Microrna Regulation On The Expression Of CD38 And Other Asthma Related Genes In Human Airway Smooth Muscle Cells by Dileepan, Mythili
MICRORNA REGULATION ON THE EXPRESSION OF CD38 AND OTHER 
ASTHMA RELATED GENES IN HUMAN AIRWAY SMOOTH MUSCLE CELLS 
 
A THESIS 
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL 
OF THE UNIVERSITY OF MINNESOTA 
BY 
 
MYTHILI DILEEPAN 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
MATHUR S. KANNAN, ADVISOR 
 
 
 
APRIL, 2015 
 
  
 
 
 
 
 
 
 
 
 
 
 
                           
                         © Mythili Dileepan 2015 
 
i 
 
 
Acknowledgements 
First and foremost, I would like to thank my mentor, Dr. M. S. Kannan, for giving me 
the opportunity to work in his lab.  And I thank him for his guidance, motivation, and 
understanding and especially for his patience.  
Secondly and more importantly I thank my committee members Dr. Pamela J. 
Skinner, Dr. David R. Brown and Dr. Subbaya Subramanian for their valuable 
suggestions, insightful comments and helpful direction throughout my studies. 
In particular, I would like to thank Dr.Antony Jude Joseph for training me in the basics 
of cell culture, molecular biology techniques and animal works.  
I am indebted to Dr. Savita Rao for her willingness to review my manuscripts, 
countless suggestions and encouragement over the years. 
I owe a big thank you to Dr. Sam. Maheswaran for offering me his moral support and 
encouragement throughout my studies. 
I thank the entire faculty in the department of Veterinary Biosciences, College of 
Veterinary Medicine for the encouragement and for being an invaluable source of 
knowledge.  
Finally, I would like to thank my parents, my husband and my kids, whose ceaseless 
encouragement and emotional support had inspired me to complete my studies.   
 
 
 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This dissertation is dedicated to the memory of my father, beloved mother and my 
loving family for always standing by me. 
 
 
 
 
 
 
 
 
 
 
iii 
 
ABSTRACT  
CD38 is a multifunctional enzyme that regulates intracellular calcium ([Ca++]i ) 
homeostasis. It is expressed in airway smooth muscle (ASM) cells where it elevates 
[Ca++]i through its enzymatic product cyclic ADPribose (cADPR) and increases ASM 
contractility. Increased expression of CD38 in the ASM cells derived from the 
asthmatic patients (AS-HASM) and attenuated airway hyperresponsiveness to 
contractile stimuli shown by CD38-/- mice implicate the importance of CD38 in 
asthma.  
The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) is 
considered to be an important mediator for airway pathology in asthma. The reason 
for the differential expression of TNF-α-induced-CD38 in AS-HASM cells, does not 
involve transcriptional regulation of CD38 which is through signaling pathways 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K), and 
transcription factors nuclear factor kappa-B (NF-κB) and AP-I. Thus I hypothesized 
that post-transcriptional regulation of CD38 by microRNAs account for the differential 
expression of TNF-α induced -CD38 in AS-HASM cells.  
Among the several potential microRNAs predicted for CD38 by microRNA 
target-predicting algorithms, I selected miR-140-3p and miR-708 for further studies, 
as these showed differential expression in the AS-HASM cells compared to those 
from healthy subjects.  
Overexpression of these either microRNAs in ASM cells inhibited the TNF-α 
induced expression of CD38 at messenger RNA (mRNA) and protein levels. 
Luciferase-reporter assays with a mutated 3’UTR of the CD38 transcript confirmed 
the specific target sites for both microRNAs. Transcript stability assays revealed that 
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mRNA degradation is not the mechanism underlying regulation by microRNAs. 
Examination of the expression and activation levels of proteins in the upstream 
signaling pathways of CD38 revealed that miR-140-3p, by inactivating p38 MAPK 
and NF-κB, and miR-708, by inactivating c-Jun N-terminal kinase (JNK) MAPK and 
Akt by elevating the expression of their phosphatases MKP-1 and PTEN respectively, 
control the expression of CD38 indirectly. 
Further, we found that miR-708 downregulates the expression of many 
chemokines and inhibits the serum induced proliferation of human ASM cells.  
We conclude that both microRNAs have therapeutic potential in controlling 
asthma related symptoms through regulating the expression of CD38 and 
chemokines and controlling the proliferation of human ASM cells.     
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1. Asthma 
1.1 Definition, characteristic features and clinical signs 
Asthma is a common chronic respiratory disorder affecting about 300 
million people worldwide (282). It is characterized by chronic inflammation, 
reversible airflow limitation and remodeling of airway structures (238). According 
to GINA report, 2014, asthma is defined as a “heterogeneous disease that is 
usually characterized by chronic airway inflammation with history of respiratory 
symptoms such as wheeze, shortness of breath, chest tightness and cough that 
vary over time and in intensity, together with variable expiratory airflow limitation.”  
These signs, including airflow typically change in magnitude over time. These 
features may resolve naturally or with treatments and remain absent for many 
months. Conversely, patients may experience episodic flare-ups of asthmatic 
symptoms that may pose a life-threatening risk.  Under the microscope the 
stained tissue sections of lungs obtained from asthmatic patients show histo-
pathological lesions such as disrupted epithelial cells, hyper plastic goblet cells, 
increased smooth muscle mass, increased fibrotic tissues, collagen deposition 
and metaplastic epithelial cells (23, 56, 140, 275, 292, 314).  
1.2 Prevalence and economic importance 
The prevalence of asthma is increasing every year and currently it is 
estimated that ~300 million people of all ages are affected world-wide (43). It is 
predicted that in 2025, an additional 100 million people will be affected by asthma 
(World Health Organization, 2007). In USA alone, the prevalence of asthma is 
increasing since 1980 and it is estimated that nearly 30 million people are 
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affected currently (U.S. Department of Health and Human Services Centers for 
Disease Control and Prevention). In 2010, 1 in 12 adults and 1 in 11 children 
were affected by asthma. According to a 2014 CDC report, the total cost of 
asthma (medical expenditures, untimely deaths, loss of productivity due to 
missed work days) in the US is $56 billion each year. In 2008 asthma caused 
10.5 million missed days of school and 14.2 million missed days of work and in 
2009 it accounted for 479,300 hospitalizations, 1.9 million emergency department 
visits and 8.9 million doctor visits. In the last decade there has been a ~15% 
increase in the number of people with asthma. Overall, health and economic 
burdens of asthma pose a serious concern in the US and the rest of the world. 
1.3 Etiology 
Both environmental factors and genetic elements influence the onset of 
asthma (75). Children are more prone to this disorder than adults (141) and it is 
the number one chronic condition responsible for school absenteeism of children 
(CDC). Male-children and female-adults are more susceptible to asthma (141). 
Other than gender and age, other genetic factors known to be involved in 
triggering asthma are obesity (40, 92, 115, 135, 214, 307), stress (27, 278, 341) , 
exercise (27) and pregnancy (61, 102, 104, 241, 339, 364).   
Environmental factors 
Environmental factors that induce asthmatic symptoms are allergens such 
as various pollens, animal hair and dander, cockroaches, chemicals, fumes and 
microbes.  Asthma caused by allergens is the most common form in the US and 
it is estimated about  50% of asthmatic cases are due to allergic asthma (248). 
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Epigenetic modulations that influence the transcriptional activity of asthma-
susceptible genes are histone modifications, DNA methylations and microRNA 
activities (295).  Epigenetic modulations influence the expression of microRNAs 
such as let-7a, miR-9, miR-34a, miR-124, miR-137, miR-148 and miR-203 (296). 
On the other hand microRNAs can affect the expression of epigenetic modulators 
such as histone deacetylase, histone acetyl transferase and DNA methyl 
transferase by interfering with their gene expression (295, 296). 
Genetic factors - Asthma susceptible genes 
Asthma is not linked to only one gene but several genes that interact with 
each other and cause asthma pathogenesis (227). Thus far, more than 100 
genes have been identified as asthma-related (315), though not all 100 genes 
may co-act to exhibit the asthma phenotype in an individual. While interplay of a 
group of genes may be involved in eliciting asthma symptoms in one individual, 
interaction of another group of genes may be responsible for inducing the asthma 
phenotype in another individual. Since asthma is associated with both genetic 
and environmental factors, carrying an asthma susceptible gene by itself may not 
result in inducing asthmatic symptoms. Exposure to and interaction with specific 
environmental triggers is also needed for an individual to demonstrate clinical 
signs. Candidate gene studies using animal models, positional cloning using 
linkage analyses, and genome wide associated studies (GWAS) have led to the 
identification of numerous asthma susceptibility genes. Candidate gene studies 
have identified many genes that are involved in the development of diverse 
biological effects such as T-helper cell-2 inflammation, regulatory T- cell function, 
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HLA locus/immunity and IgE response of B cells (184). Using linkage studies 
new genes have been recognized (227) . They are A disintegrin and 
metalloproteinase domain-containing protein 33 (ADAM33) (337) , DPP10 (8), 
PHF11(372), HLA-G(253), and GPRA (199) with a role in atopy, airway 
hyperresponsiveness (AHR) and elevated IgE levels. GWAS studies identified 
genes including IL1RL1(132), TSLP(35), IL33, HLA-DP (254), ORMDL3 (243), 
and Childhood Management Program cohort found genes including PDE4D,  
IRAK-3, PHF11, IL10, ITGB3 (287), IL13 (159) , and IL4R (159). These genes 
appear to be involved in irregular inflammatory/immunologic responses.  Some of 
these genes have been already studied and have been shown to be involved in 
the pathogenic pathways of asthma (212). For example, the gene ADAM33 is 
associated with bronchial hyperresponsiveness (212). The ORLMD3 gene 
product is  regulating ER-mediated Ca2+ signaling and cellular stress (55) as well 
as sphingolipid homeostasis (47) and is associated with the stress-related 
signaling molecule c-Jun N-terminal kinase (JNK) (336). Chemokines CCL11 and 
CCL5 are also identified as asthma susceptible genes (342). From these 
findings, it is clear that asthma is a complex disease involving many mechanisms 
and pathways.  
2. Asthma phenotypes 
Multiple etiological origins and differences in the pathogenesis of the disease 
cause heterogeneity in asthma phenotype and, there is no strong correlation 
between pathological features and clinical symptoms or treatment response. 
Many asthma phenotypes identified in humans are clustered according to 
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etiology, clinical severity, steroid treatment response, appearance of histo-
pathological lesions and onset of asthma in life (42, 333) as shown in Table 1. 
Based on etiology, patients are grouped into allergic asthma, non-allergic asthma 
(viral infection, occupational asthma) and intrinsic asthma (exercise-induced, 
stress-induced asthma). Allergic asthma often starts in childhood and responds 
well to inhaled-gluco-corticosteroids (ICS). Induced sputum of these patients will 
have readily seen eosinophils. Most of the time, non-allergic patients do not 
respond well to ICS treatment and their induced sputum may have neutrophils or 
eosinophils or very few inflammatory cells. When clinical severity ( frequency of 
asthma attacks, FEV1 and other asthma symptoms) is considered, patients are 
grouped into mild, moderate and severe. According to histo-pathological lesions, 
there are two sets of asthmatic patients, those who have eosinophilic asthma and 
those with neutrophilic asthma (346). Physicians sometimes categorize asthmatic 
patients , into steroid responders and steroid non-responders (229), and patients 
with childhood onset and adult onset asthma (346). Mostly, severe asthmatic 
patients need higher doses of ICS or systemic administration of steroids to 
control the symptoms of asthma or they do not respond to steroids at all. Patients 
with adult onset asthma, especially women, often show refractory asthma, a form 
of severe asthma that does not respond to treatments. Existence of a variety of 
phenotypes indicates that asthma therapy needs to be tailored to the phenotype 
and the pathogenic mechanism causing asthma. 
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Table 1: Asthma phenotypes  
Etiology Allergic asthma, non-
allergic asthma, intrinsic 
asthma 
Clinical severity Mild, moderate, severe 
Histo-pathological lesions Eosinophilia, neutrophilia 
Response to corticosteroid 
therapy 
Steroid responders and 
steroid non-responders 
 Onset Childhood onset and adult 
onset 
 
3. Asthma diagnosis 
Diagnosing asthma before starting any treatment is essential since many other 
disease conditions also present with apparently similar clinical signs. The steps 
involved in making a diagnosis of asthma are as follows: 
a. History of clinical symptoms  
Whether the clinical symptoms worsen at night, vary over time and in intensity, 
are increased by exposure to allergens/irritants, climate change, exercise or 
strong smoke (tobacco and cigarette smoke, indoor household solid fuels).  
b. Physical examination  
During the physical examination, expiratory wheezing on auscultation may be 
present. If the asthma is severe, it may not be possible to hear any wheeze due 
to severely limited airflow caused by increased obstruction of airways. While 
expiratory wheezing may be present in other respiratory diseases, inspiratory 
wheezing is not a feature of asthma. 
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c. Spirometry - Lung/Pulmonary function tests (PFT) 
PFT provide information about the level of lung function impairment and serves 
as a tool to evaluate the level of improvement after treatment, i.e. treatment 
response. The values from PFT of asthmatic subjects are compared with values 
seen in normal healthy individuals of similar age, height, gender and race as well 
as with results of previous PFT. These tests help in the identification of diseases 
such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary 
fibrosis. 
I.  Peak Expiratory Flow (PEF).  
This measures the amount of air one can exhale to the best of their capability. It 
is unreliable because measurements may differ from instrument to instrument by 
20% resulting in false positive or false negative results.  
ii.  Forced Vital Capacity (FVC) 
Here, one inhales as deeply as possible and then exhales as forcefully as 
possible. Measurement of the amount of exhaled air is called FVC.     iii.          
Forced Expiratory Volume in 1 second (FEV1) 
This measures the maximum amount of air one can forcefully exhale in one 
second after full inspiration.  An FEV1 that is less or more than 12% of baseline 
(before the use of broncho dilator) and less or more than 200 ml from baseline 
(before the use of broncho dilator) after the administration of a bronchodilator is 
considered as improved lung function. Since reduced FEV1 may be present in 
other disease conditions, a ratio of FEV1/FVC yields a more reliable indication of 
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airflow limitation. A ratio that is lower than 0.75-0.8 is considered as being 
indicative of asthma. This is more trustworthy than peak expiratory flow. 
iii. Provocation Test - Methacholine Challenge Test 
This test is performed when clinical symptoms and spirometry results do not 
clearly establish a diagnosis of asthma. Methacholine is a spasmogen which 
causes asthmatic airways to contract involuntarily and constrict rapidly at 
concentrations much lower than in a healthy subject. This test enables detection 
of how responsive or irritable the airways are to methacholine. Spirometry is 
done before and after each dose of the methacholine challenge. A 20% reduction 
in FEV1 relative to baseline is considered as a positive indication of asthma and 
the methacholine concentration that causes a positive reaction is referred to as 
PC20. To distinguish asthmatic patients from healthy subjects, usually 8 to 16 
mg/mL methacholine is used as an optimal cut off range. Inhaled histamine or 
exposure to cold air can also be used in this test instead of methacholine. 
4. Asthma in animals  
Dogs (330), cats (76) and horses(149) can develop asthma-like symptoms 
as in humans. However, cats and horses are more prone to develop these 
symptoms compared to dogs.  The disorder is referred to as allergic bronchitis in 
dogs, feline asthma or allergic bronchitis in cats and recurrent airway obstruction 
or heaves in horses (149)  (Merck Veterinary Manual). In these animals, the 
symptoms can be triggered by pollen, hay, straw, cigarette smoke, wood burning 
stoves, fire places, carpet or floor cleaners, deodorizers, air fresheners, dust, dry 
air, exercise, viruses, cold temperatures, rapid breathing due to exercise, 
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chemicals in the air, etc. Animals show symptoms such as difficulty in breathing, 
shortness of breath, wheezing, open-mouth breathing, cough (dry, hacking), pale 
mucous membranes (bluish gums and tongue), lethargy, exercise intolerance, 
lack of appetite and weight loss (Merck Veterinary Manual). Animals are treated 
with glucocorticoids, antihistamines and bronchodilators to relieve these 
symptoms (119) (Merck Veterinary Manual).  
5. Animal asthma models  
For asthma-related laboratory studies, mice are widely used as an animal 
model due to the following reasons: they are closely related to humans with 
respect to genome sequences, easier to handle, easier for genetic manipulation, 
comparatively less expensive, fast breeding due to a shorter gestation period and 
readily available reagents and tools for analysis. Further, mice are known to 
exhibit an asthma phenotype when exposed to pro-inflammatory cytokines (54, 
188, 373).  
Guinea pigs are also used in asthma studies. Advantage of using them is, 
they show immediate and late phase airway responsiveness, but the 
disadvantage is, their major anaphylactic antibody is IgG. While rabbits show 
immediate and late phase airway responses and advantageously produce IgE as 
their primary anaphylactic antibody but neonatal immunization is needed for late 
phase airway responses (302). Other animal models for asthma such as sheep, 
pigs and horses (7, 50, 156) also have been used. However, they are not very 
popular due to the lack of availability of appropriate tools and reagents for 
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analysis as well as cost ineffectiveness of conducting experiments using these 
models (302).  
6. Functions of Airway Smooth Muscle (ASM) cells 
ASM cells are important structural cells in the airways. They are known to 
maintain bronchial tone and mediate bronchoconstriction in response to foreign 
bodies and stimuli. ASM cells were recently recognized to have a role in 
inflammation. They secrete pro-inflammatory mediators such as cytokines, 
chemokines, growth factors, ECM proteins, etc., express receptors for these 
molecules and act as immuno-modulatory cells (358) that can function in an 
autocrine or paracrine manner (80). The secreted inflammatory mediators 
promote AHR during acute inflammation (53) and induce proliferation of ASM 
cells and altering the structure of the airway wall during chronic inflammation 
(185).  
Structural changes in the airways are a significant component of the 
pathogenesis of asthma. The increased ASM mass in the airway wall is thought 
to be due to ASM cell proliferation, ASM cell hypertrophy, prolong survival of 
ASM cells, transformation and differentiation of fibroblasts into myofibroblasts 
and then to ASM cells. In addition, increased airway ASM mass could be caused 
by migration of vascular smooth muscle cells to airways, differentiation of stem 
cells in the peripheral blood or the airways into ASM cells, migration and 
transformation of epithelial cells into ASM cells via the process of epithelial 
mesenchymal transition. Since ASM cells participate in the development of all 
three cardinal features of asthma namely, AHR, inflammation and remodeling of 
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airway wall, they are considered to be a distinct and attractive therapeutic target 
for asthma.  
7. Airway inflammation 
7.1 Mediators and cells involved in pathogenesis 
Asthma triggering agents induce and maintain chronic inflammation 
through a variety of mediators like histamine, immunoglobulin E (IgE), 
prostaglandins and leukotrienes (26).  Table 2 lists the different types of 
mediators and their functions in detail. This table is adapted from a review 
article published in 1998 by The American  
Society for Pharmacology and Experimental Therapeutics (26). The cells 
involved in producing these mediators are epithelial cells, dendritic cells, T-cells, 
B-cells, mast cells, macrophages, eosinophils and ASM cells (28, 247).  
Epithelial cells produce Thymic Stromal Lymphopoietin, when they encounter 
allergens and induce dendritic cells to process the allergens and present them to 
T-lymphocytes (72). Once T-cells are activated by the antigen-priming, they 
produce interleukin IL-13 and IL-4 to induce B-cells and IL-5 to induce 
eosinophils (71, 143). Induced B-cells produce antigen specific immunoglobulin E 
(IgE) which binds to the surface of mast cells. Cross linking of IgEs by the 
allergen  activates mast cells to de-granulate and various mediators such as 
histamines and prostaglandins and de nova synthesis and release of 
leukotrienes resulting in recruiting more inflammatory cells to the site (71). The 
above mechanism is depicted in Figures 1 and 2. IgE can also bind to 
macrophages and induce them to release inflammatory mediators (71).  
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Figure i: Common mechanism for allergic asthma 
 
Figure ii: Cross-linking of allergens with IgE  
 
 
7.2 TH2 biased inflammation and hygiene hypothesis 
   Changes in the environment along with epigenetic factors are thought to 
be the major causes for the recent enhancement in prevalence of asthma (144). 
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These factors influence the severity of the disease and responsiveness to 
therapy (247). The main hypotheses regarding increased prevalence of asthma 
are the hygiene hypothesis and the hypothesis based on TH1–TH2 imbalance 
(111, 332) as a result of increased urbanization.  The “hygiene hypothesis” is a 
widely accepted hypothesis to explain the prevailing increased frequency of 
allergic asthma.  It suggests that increased susceptibility to allergic diseases in 
urban children is due to less exposure to symbiotic microbes resulting in the 
suppression of natural development of the immune system relative to children 
living in a farm environment (130, 257). Diminished exposure to certain 
organisms such as Hepatitis A virus (235)  Fungi (Eurotium and Penicillium) (1)  
and Mycobacterium (69, 303) in early life results in a less robust and defective 
immune system which in turn leads to many chronic inflammatory disorders 
including asthma.  For thousands of years our ancestors have been exposed to 
helminths and harmless environmental saprophytes that live in decomposing 
matter. Continuous exposure of the gut to helminths and saprophytes  enables 
regulatory dendritic cells to continuously sample the gut contents, allergens and 
self (290), thus keeping the immune system in check. A subsequent detection of 
a “known” pathogen of a specific pattern by Toll like receptors results in the  
recruitment of specific T-reg cells to act on the allergen and suppress the 
inflammation (333, 365). This process is called immune tolerance. Because of 
the recent Westernization associated with hygienic measures, these exposures 
have been minimized to a large extent in current conditions and changed the 
gut/airwaymicrobiome. The lack of early exposure to these beneficial organisms 
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leads to the defective development and regulation of the immune system, 
intolerance to allergens and endotoxins, and increased susceptibility to allergic 
inflammation (289).  
 The hypothesis about TH1 and TH2 imbalance states that people who 
lack induction of the TH1 pathway by viral or bacterial infections early in their life 
are prone to having an activated TH2 pathway later in their life (117, 176). 
Hepatitis A virus (HAV) infection, which occurs through orofecal route, has a 
receptor on human lymphocytes called ‘T cell immunoglobulin domain, mucin-like 
domain-1’ (TIM-1). This receptor is involved in regulating a subset of T 
lymphocytes. The binding of HAV to TIM-1 receptor on lymphocytes might 
suppress the TH2 response and enhance the T-reg response which is anti-
inflammatory (235, 335).  
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Table ii. Inflammatory mediators and functions 
 Mediators names Function 
Amine 
mediators 
  
 Histamine 
 
Bronchoconstriction, airway 
secretion, plasma exudation, 
neural effects, chemotaxis 
 Serotonin  
 
Plasma exudation, neural effects 
              
 
Adenosine Neural effects 
Lipid-derived 
mediators 
  
Prostanoids PGD2 and PGF 2α 
 
Bronchoconstriction, airway 
secretion, neural effects 
 PGE2 
 
Airway secretion, neural effects 
Thromboxane 
(Tx) 
 Bronchoconstriction, plasma 
exudation, neural effects, AHR 
Leukotrienes 
 
LTB4 
 
Chemotaxis 
 LTC4, LTD4& LTE4 
 
Bronchoconstriction, airway 
secretion, plasma exudation, 
chemotaxis  
Peptide 
mediators 
Bradykinin 
 
Plasma exudation, 
bronchoconstriction, airway 
secretion 
 Tachykinins-
Substance P 
 
Neural effects, 
bronchoconstriction, airway 
secretion, plasma exudation 
 Tachykinins-NKA Bronchoconstriction, airway 
secretion, plasma exudation 
 Endothelins 
 
Bronchoconstriction, airway 
secretion, plasma exudation, 
neural effects 
 Complement Chemotaxis, bronchoconstriction, 
airway secretion, plasma 
exudation 
Small 
molecules 
Reactive oxygen 
species 
 
Airway secretion, plasma 
exudation 
 Nitric oxide Airway secretion, neural effects, 
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chemotaxis 
Cytokines Lymphokines - IL-
2, IL-3, IL-4, IL-5, 
IL-IL-13, IL-15, 
IL-16, and IL-17 
 
Eosinophil growth, maturation, 
activation and migration; T 
lymphocyte, growth, 
differentiation, proliferation and 
activation; activation of other cells 
like macrophages, B cells, 
neutrophils, epithelial cells, 
endothelial cells, fibroblasts. 
 Pro-inflammatory 
cytokines-IL-1, 
TNF, IL-6, IL-11, 
GM-CSF, and SCF 
 
Adhesion to vascular endothelium, 
growth factor for B cells, Th2 cells, 
neutrophil chemoattractant, T cell 
and epithelial cell activation, 
activation of fibroblasts, 
proliferation and maturation of 
hematopoietic cells, endothelial 
cell migration, growth factor for 
mast cells 
 Inhibitory cytokines 
-IL-10, IL-1Rα, IFN-
γ, IL-12, and 1L-18 
Inhibits eosinophil survival, inhibits 
eosinophil influx after allergen, 
decrease the proliferation of TH1 
and TH2 cells, decrease the 
activation of macrophages, 
increase the growth of B cells, 
natural killer cells and mast cells,  
Growth 
factors 
PDGF, TGF-β, 
FGF, EGF, and 
IGF 
Fibroblast and ASM proliferation, 
release of collagen, fibroblast 
proliferation, chemoattractant for 
monocytes, fibroblasts, and mast 
cells, 
Chemokines  Attract leukocytes into tissues 
Proteases Mast cell tryptase, 
mast cell chymase 
and matrix 
metalloproteinases 
 
Tryptase increase the 
sensitiveness of airways to 
histamines, proliferation of ASM 
cells; chymase activates TGF-β 
and induces fibroblast proliferation  
18 
 
 
However, not all viral infections, i.e., measles, mumps, chickenpox and herpes 
viral infections, would provide protection against chronic inflammation by calming 
the TH2 responses (31, 232, 251).  
7.3 Storage of inflammatory mediators  
Many inflammatory mediators, cytokines and chemokines, are stored 
within intracellular compartments such as secretory granules, Weibel-Palade 
(WPB) body and vesicles in inflammatory cells and airway structural cells. These 
stored mediators can be differentially released depending on the pathways 
involved such as degranulation (piecemeal degranulation, anaphylactic 
degranulation), exocytosis, and secretion. 
In endothelial cells, WPB stores eotaxin-3 and IL-8 whereas small 
granules other than WPB, store CXCL1 and CCL2 (81). Their exocytosis may be 
regulated by elevated levels of intracellular Ca++, cAMP or phorbol esters (58). It 
has been found that these small granules are distinctly regulated by Protein 
Kinase A and Protein Kinase C compared to WPB in endothelial cells (58, 260).  
Mast cells release inflammatory mediators and other substances through 
constitutive exocytosis and regulated exocytosis (99). Constitutive exocytosis 
happens throughout the lifetime of a cell without a stimulus. Regulated 
exocytosis occurs with a clear stimulus like pH, osmolarity changes, binding of 
ligands to receptors etc. Many secretory pathways are involved in differentially 
releasing the substances to various stimuli. Degranulation involves in readily 
releasing the preformed mediators that are stored in granules, to a stimulus.  In 
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secretion, substances are moved from one containment to another through an 
active process. Exocytosis occurs when vesicles trafficking to the plasma 
membrane, fuse with it and release to the environment. In mast cells, two types 
of degranulation have been identified. One is piecemeal degranulation (PMD) 
and the other one is anaphylactic degranulation (AND) (98, 99). PMD involves 
selective release of substances from granules without fusion with plasma 
membrane or with other granules. In contrast, AND involves granule to granule 
and granule to plasma membrane fusion and a burst of release of granule 
contents mediated by soluble N-ethylmaleimide-sensitive factor attachment 
protein receptors (SNAREs) (245). Calcium flux is important for mast cell 
degranulation (107, 245). Several molecules are involved in mast cell 
degranulation such as Rac1, Rac2, Rab27b (305), Rab3d (285), Cdc42 (157), 
MARCKS (139), etc.  
Many signaling pathways are known to participate in the expression and 
release of inflammatory mediators. Table 3 shows various pathways involved in 
chemokine expression and release in different cell types.  
Table iii. Pathways involved in chemokine expression and release  
Inducer Pathway Chemokin
e 
expressio
n 
Chemokin
e release 
Reference Cells 
IL-13  MAPK and 
STAT-6  
 CCL11 Peng et al, 2004  HASM 
TSLP MAPK and 
STAT-3  
CCL11, 
CXCL8  
 CCL11, 
CXCL8 
Shan et al, 2010  HASM 
IL-1β  MAPK, NF-
κB  
 CCL11, 
CCL2 and 
CCL7 
CCL11, 
CCL2 and 
CCL7 
Wuyts et al, 
2003 
 HASM 
TNF-α  JNK MAPK  CXCL1    Lo et al, 2014 Vascular 
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endothelia
l cells  
TNF-α  p38 MAPK 
and PI3K 
  CXCL1  Lo et al, 2014 Vascular 
endothelia
l cells 
IL-17A  MAPK CCL11  CCL11  Rahman et al, 
2006 
HASM 
IL-17 + 
IL-1β 
MAPK and 
PI3K 
CXCL8  CXCL8 Dragon et al, 
2007 
HASM 
IL-31 MAPK CCL2 CCL2 Wai et al, 2007 Bronchial 
epithelial 
cells 
 
7.4 Extracellular matrix 
The ECM not only supports structural and immune cells (198) in the lung 
but actively participates  in controlling ASM proliferation (152, 252, 313), ASM 
contractility (86, 153) and secretion of inflammatory mediators (60). Through 
changing the phenotypes of ASM cells, the ECM alters the functions of airway 
wall. 
During asthma, ECM components such as collagens, proteoglycan, 
hyaluronan, tenascin-C, versican, elastin, fibronectin, and MMP-1 are aberrantly 
expressed (18, 274). Severe asthmatic patients with persistent asthma and 
permanent structural changes show increased deposition of fibronectin and 
collagen in the sub-epithelial matrix (153). Fibrillar forms of collagen present in 
the ECM bind to ASM cell integrins and influence the rigidity, distensibility and 
the structural stability of ASM cells (36). Consequential mechanical tension in the 
cell wall induces ASM cell differentiation. Furthermore, elastin, MMPs-1, 9 and -
12 are highly expressed between the ASM bundles in asthmatic patients (19, 
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288). Altered concentration of the components of ECM in the lungs promotes 
ASM cell proliferation and migration. 
8. Airway hyperresponsiveness (AHR) 
Excessive ASM contraction occurs in asthmatics (223) due to increased 
actin–myosin coupling (261). Increased concentration of [Ca++]i induces 
contraction of ASM cells through myosin light chain by two pathways. One is 
through calmodulin, which binds to Ca++ and activates the myosin light chain 
kinase (MYLK) by phosphorylating it. MYLK in turn activates myosin light chain 
(109, 370). The other pathway is through the small GTPase, RhoA. Increased 
[Ca++]i induces loading of GTP onto RhoA, which in turn induces Rho associated 
coiled-coil–containing protein kinase (ROCK) to directly phosphorylate myosin 
light chain phosphatase and inactivate it (163). This causes increased 
phosphorylation of myosin light chain.  
[Ca++]i can be increased by acetylcholine released from parasympathetic 
nerves that innervate ASM (150).  Acetylcholine binds to G-protein coupled M2 
muscarinic receptors, which recruit Gq subunit intracellularly (150). This activates 
phospholipase C (PLC) which phosphorylates Phosphatidylinositol 4, 5-
bisphosphate (PIP2) to produce Inositol trisphosphate (IP3) (105). IP3 is a potent 
second messenger for Ca++ released from the sarcoplasmic reticulum to 
cytoplasm.  
Increased extracellular concentration of potassium ions causes opening of 
voltage-gated calcium channels in the plasma membrane and thus increases 
[Ca++]I (105). During asthma, TH2 and TH1 cytokines at increased levels, bind to 
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G-protein coupled receptors (GPCR) and induce various signaling pathways to 
increase [Ca++]i(334).  
Further, integrins are important transmembrane proteins that link the 
intracellular actin-myosin cytoskeleton to the ECM (136). Smooth muscle 
contraction due to the interaction between actin and myosin that is mediated by 
integrins and the ECM is translated into forceful narrowing of the airway wall. 
This is dependent on the strength of binding of ASM cells to the underlying ECM. 
Narrowing of the airway wall can occur with changes in the ECM even in the 
absence of changes in actin-myosin interactions (239, 369).    
Increased airway wall thickness due to ASM cell proliferation can also cause 
increased airway contractility (13, 200, 353).  
9. Airway remodeling 
9.1 Pathological features 
Airway remodeling in asthma has been recognized for over a hundred 
years. However many aspects of this pathological feature such as etiology, 
molecular/cellular mechanisms and relevance to physiology and clinical outcome 
are still not well understood. Among asthmatic patients, only 5-10% of them are 
severely affected (326). However, they are responsible for a large portion (>50%) 
of asthma-related costs (300). Most of the severely affected asthma patients 
have substantial remodeling of the airways. Currently available asthma therapies 
do not control airway remodeling, and this drives the need for continued research 
in this area to develop drugs that can resolve remodeled airways. 
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Characteristic features of airway remodeling include increased ASM mass, 
sub-epithelial fibrosis, goblet cell hyperplasia, sub-mucosal mucus gland 
hypertrophy, desquamation of epithelium, formation of new blood vessels and 
increase ECM deposition (63, 74, 259). Narrowing of the airway lumen and 
obstruction in airflow are a consequence of increased ASM mass through 
generation of greater force when airways contract. Meanwhile, persistent airway 
obstruction is also caused by hyperplasia of sub-epithelial fibroblasts (41, 242). 
9.2 Role of ASM cells in remodeling  
Changes in smooth muscle properties from contractile to proliferative due to 
several environmental stress are fundamental to the increase in ASM mass.  
Many studies have shown that asthmatic subjects exhibit increased ASM mass 
which is one of the important structural changes observed in airway remodeling 
(56). This could be due to smooth muscle hyperplasia, hypertrophy, decreased 
apoptosis, migration of smooth muscle cells from other places (vascular smooth 
muscle, stem cells) and differentiation of fibroblasts into smooth muscle cells. 
While TH2-derived chronic inflammation was thought to be the cause of airway 
remodeling, increasing evidence questions this belief. For instance, the 
augmented ASM mass observed in some children with severe asthma has not 
been associated with inflammation (38) 
Human ASM cells derived from asthmatic or healthy subjects have been 
shown to proliferate in response to a wide array of mitogenic factors (Table 4).  
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Table iv. Mitogenic factors for ASM cell proliferation 
 
 
 
 
 
 
 
 
 
 
 
 
Mitogenic factors induce ASM proliferation by activating signaling 
pathways through the receptors such as receptor tyrosine kinase (RTK) or G-
protein coupled receptors (GPCR). Two distinct downstream signaling pathways 
of these receptors, namely phosphoinositide 3-kinase (PI3K) and extracellular 
signal-regulated kinase (ERK), have been identified as major pathways that 
independently induce ASM cell proliferation (52, 195). Both pathways control the 
expression/activation of cyclin D to exert their proliferative function (263, 265). 
PI3K targets the downstream small GTPase Rac1 which activates the cyclin D1 
promoter through the cAMP response element binding protein (CREB). This 
results in activation of the transcription factor (ATF)-2 binding site. Rac1 is a part 
Mitogenic factor Examples 
Growth factors Platelet derived growth factor (PDGF), epidermal 
growth factor (EGF) 
Cytokines  TNF-α, TGF- β 
Chemokines  CCL3, CCL5, CCL11 
Inflammatory 
mediators   
Histamine, endothelin, thromboxane A2, 
sphingosine 1-phosphate 
Enzymes  Tryptase, thrombin,  elastase, MMP 
ECM components  Fibronectin, Collagen 1 
Others Reactive oxygen species, mechanical stretch 
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of the NADPH oxidase complex which produces H2O2 in response to mitogens. 
Cells treated with mitogens and antioxidants showed attenuated expression of 
cyclin D1 and H2O2, indicating that mitogens induce ASM cell proliferation 
through the PI3-kinase/Rac1/NADPH oxidase pathway (46, 264). It has been 
found that human ASM cells derived from asthmatic patients (AS-HASM) are 
more proliferative than cells derived from non-asthmatic healthy subjects (NA-
HASM) (175). Furthermore, studies have shown that AS-HASM cell proliferation 
is regulated by the PI3K pathway and NA-HASM cell proliferation is controlled by 
the ERK MAPK pathway (52). This intrinsic defect in AS-HASM cells is thought to 
be due to decreased expression of CCAAT-enhancer-binding proteins (C/EBPα) 
(280) or changes in [Ca++]i homeostasis (327). C/EBPα decreases the expression 
of cell-cycle inhibitor p21 which in turn increases ASM cell proliferation. 
Increased biogenesis of mitochondria leading to ASM cell proliferation was noted 
when there was an abnormal influx of extra cellular Ca++ along with activation of 
peroxisome proliferator-activated receptor γ-coactivator-1α (PGC-1α), nuclear 
respiratory factor-1 (NRF-1), and mitochondrial transcription factor A (mtTFA) 
(327). 
TGF-β is increasingly expressed in the airways of severely affected 
asthmatic patients relative to healthy subjects (284). It induces fibroblasts to 
produce ECM and ASM to increase their cellular size(284). On the other hand, it 
was noted that TGF-β either increases or inhibits ASM cell proliferation (110). 
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10. Asthma therapy 
10.1 Current treatment for asthma  
While there is no current cure for asthma, it can be successfully controlled 
by avoiding exposure to asthma triggers, proper monitoring of asthma symptoms 
and preventive check-ups. Nasal nebulizers containing broncho-dilators such as 
short acting β2-adrenergic receptor agonists or anti-cholinergics along with 
inhaled glucocorticoids are used to control exacerbations (58). Short acting β2-
adrenergic receptor agonists are given to relax the ASM, dilate airway walls, and 
increase air flow. This can be achieved within five minutes and lasts up to 3-6 
hours. Use of β2-adrenergic receptor agonists, alone in patients with severe and 
persistent asthma, leads to exacerbation of asthmatic symptoms with increased 
mortality (258).  In addition, patients using this drug for extended periods of time 
may develop tolerance due to down regulation of β2-adrenergic receptors. 
Simultaneous use of β2-adrenergic receptor agonists and glucocorticoids has a 
beneficial effect as it increases the number of β2-adrenergic receptors by 
inducing receptor gene expression. Glucocorticoids bind directly to the 
glucocorticoid response element (GRE) in the promoter region of β2-adrenergic 
receptor gene and transcriptionally enhance gene expression (174). During 
asthma, the activity of histone deacetylase (HDAC) decreases while that of 
histone acetyl transferase (HAT) increases. Generally, this causes increased 
expression of pro-inflammatory genes. An added benefit of corticosteroid 
treatment is that it inhibits HAT by recruiting HDAC2 to the activated pro-
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inflammatory gene complex and represses pro-inflammatory gene expression 
(25).  
For long-term treatment, patients are prescribed inhaled long-acting β2-
adrenergic receptor agonists (LABAs) with inhaled glucocorticoids and in severe 
asthmatic conditions, systemic glucocorticoids are used.  Prolonged and frequent 
use of systemic glucocorticoids causes side effects such as suppression of 
hypothalamic-pituitary axis, reduced growth rate in children, obesity and reduced 
bone density (218). As alternative controller therapy, there are many other drugs 
available such as leukotriene modifiers, anti IgE therapy, theophylline or mast 
cell stabilizers (362). Leukotriene modifiers either antagonize leukotriene 
receptors or inhibit activation of the 5-lipoxygenase pathway thus decreasing the 
availability of bronchocontrictive peptidoleukotrienes (189, 213, 349). All of these 
alternate controller treatments are relatively less effective than glucocorticoids 
and not all patients respond to them. Non-medicinal treatments such as yoga, 
homeopathy, ayurveda, and acupuncture are also sometimes employed to 
control symptoms (57-59). The following table lists the various groups of 
available drugs, their names and function. 
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Table v: Current treatment options for asthma  
Group Sub- Group Drug Examples Action 
Broncho-
dilators 
Short-acting β2-
agonists, Long-
acting β2-agonists, 
Anti-cholinergics 
Salbutamol 
Formoterol, 
Salmeterol 
Tiotropium 
(Spiriva) and 
ipratropium 
bromide. 
 
Relaxing smooth 
muscle cells 
Glucocorticoids Inhaled 
glucocorticoids 
Prednisone Transactivation of 
anti-inflammatory 
proteins by binding to 
GRE and 
Transrepression    of 
pro-inflammatory 
proteins by blocking 
translocation of 
transcription factors 
to nucleus and 
recruiting HDAC2. 
Leukotriene 
modifiers 
 Montelukast and 
Zafirlukast 
Antagonism of 
cysteinyl-leukotriene 
type 1 receptors 
Leukotriene 
modifiers 
 Pranlukast and 
Zileuton 
Inhibition of the 5-
lipoxygenase 
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pathway of 
leukotriene 
metabolism 
Mast cell 
stabilizers 
 Cromolyn Inhibits degranulation  
Monoclonal 
anti-IgE 
antibody  
 Omalizumab Inhibits IgE binding to 
mast cells 
PDE4 inhibitors  Rolipram/ 
Methylxanthines 
Inhibits enzyme PDE 
and increase the 
concentration of 
cAMP 
Monoclonal 
antibody to 
block receptor-
IL4Rα 
 Dupilumab Simultaneously 
blocking IL4 and IL13 
Antibody 
against TSLP 
In clinical trials AMG 157 Blocks development 
of Th2-inflammation. 
Serotonin 
antagonist 
In clinical trials 5-HT (5-hydroxy 
tryptamine) 
Reduces 
inflammation 
 
Major limitations of current therapies for asthma are multiple etiologies 
and incomplete understanding of the underlying mechanisms of asthma 
development. In general, glucocorticoids are effective as an asthma symptom 
controller in about 90% of asthmatic patients. However, there is a certain 
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percentage of patients (5-10%) refractory to glucocorticoid therapy (256). 
Another disadvantage of steroid therapy is unwanted side effects as they are 
broad spectrum drugs. Severe asthmatic patients who use glucocorticoid inhalers 
for extended periods of time are known to develop systemic side effects such as 
decreased bone density, obesity, depression, retardation in growth and hormonal 
imbalances.  Long time users of inhalers are also known to develop oral thrush 
(147). Using spacers may reduce this Candida infection since spacers reduce the 
deposition of drugs on oral surfaces. 
10.2 Studies aimed at developing treatment options 
Despite effective control of symptoms in a majority of asthmatic patients 
by corticosteroid therapy, in the small portion of severely affected patients that 
are refractory (256), even high oral doses of steroids or other maintenance 
therapies such as leukotriene receptor antagonists are ineffective. In recent 
years, many potential therapeutic targets have been evaluated and progressed to 
human clinical trials in order to develop new treatment strategies for severe 
asthmatics who are refractory to current therapies.  New treatment approaches 
are aimed at reducing airway inflammatory cells (eosinophils and neutrophils) 
and ASM mass, optimizing airway caliber and blocking specific effector 
mechanisms (256).  
Patients with refractory asthma have multiple phenotypes caused by 
various pathogenic origins that may be responsible for different mechanisms 
leading to the development and persistence of airway inflammation and 
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remodeling. Thus, targeting any single effector molecule or effector cell may 
control asthma symptoms in some patients, but may not be effective in others. 
10.2.1 Enhancing bronchodilation 
Studies have found that adding a long–acting muscarinic cholinergic 
receptor antagonist (LAMA), such as tiotropium or aclidinium bromide to the 
standard regimen of corticosteroids and long-actingβ2-adrenergic receptor 
agonists (LABA), has improved lung function in severe asthmatic patients (125). 
Another study showed LAMA works better than LABA with corticosteroids in 
severe refractory asthma (256), although other studies have reported that 
tiotropium causes side effects such as difficulty in urination and retention (125).     
10.2.2 Reducing ASM mass: Bronchial Thermoplasty 
Drugs that are currently available for asthma are able to control airway 
inflammation and AHR. However, there are no medications available to reduce 
remodeling of structural tissues such as the increased ASM mass seen in severe 
asthma. Due to the presence of increased amount of smooth muscle mass and 
excessive contraction of airway smooth muscle cells in asthma, attempts have 
been made to reduce the muscle mass by a method called bronchial 
thermoplasty. It is a new, non-drug, minimally invasive procedure developed to 
treat patients with severe persistent asthma.  Bronchial thermoplasty is 
performed by delivering a specific amount of radiofrequency thermal energy to 
the airway wall. A flexible bronchoscope is inserted through the mouth or nose 
and gently pushed to reachable airways (~3-10 mm) of the patient’s lungs. A 
catheter system is extended through the tip of the bronchoscope to make contact 
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with the airway wall and expose it to thermal energy of ~ 65°C. Radiofrequency 
ablation has been used to treat cardiac arrhythmias and lung cancer as well. This 
technology was first tested in animal models before use in humans. In animal 
studies, it was found that bronchial thermoplasty destroys the actin-myosin 
interaction, disrupting the ASM contractile process (100).  
This is performed in patients who are 18 years of age or older and have 
severe asthma that is not controlled by inhaled corticosteroids and long-acting 
β2-adrenergic receptor agonists.  The procedure is performed over three 
separate visits and has been found to be effective for up to five years (348).   
This approach showed improvement in lung function (57, 170). But the 
disadvantage of this approach is that it can be done only in the larger airways 
and it could result in unwanted effects like collapse of lungs.  
10.2.3. Decreasing airway inflammatory cells  
In order to suppress eosinophilia in severe refractory asthma, specific 
antibodies and antisense RNAs have been employed.  A monoclonal antibody  
against IL-5 (hMAb, mepolizumab) (345), antisense RNA against the common 
beta chain of cytokine receptors that regulates IL-5, IL-3 and GM-CSF(6) 
(needed for the eosinophil maturation and migration) and antisense RNA against 
the CCR3 receptor that regulates eosinophil recruitment mediated by the 
chemokine eotaxin have all been tested and  shown to help  in controlling 
asthmatic symptoms (123).   
For suppression of neutrophilia, an antagonist of CXCR2, a receptor that 
mediates the effects of the chemokine IL-8 and an  antagonist of chemoattractant 
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receptor-homologous molecule expressed on Th-2 cells (CRTh2) which gets 
activated by prostaglandin D2 have been evaluated. Blockade of these receptors 
was found to enhance lung function and reduce asthmatic symptoms (164). 
10.2.4 Obstructing airway inflammatory effector mediators 
Many studies have been carried out to prevent the binding of cytokines IL-
4 and IL-13 to the alpha chain of their common receptor using antibodies. These 
cytokines are necessary for IgE production. Mixed results were obtained in 
different studies, with some reporting improvement in symptoms and others not.  
The existence of multiple mechanisms of asthma pathogenesis may explain the 
variation in the outcome of these studies (16). 
Treatment with hMAb and antisense RNA against the mediator IL-5 
effectively controlled asthma exacerbation (123, 345). Blocking of IgE binding to 
its receptor (Fc€R1) with MAb (omalizumab) also proved to be an effective 
therapy for refractory asthma (291, 299, 331). Recently antibodies against TSLP 
(124) and agonists at serotonin receptors (5HT2) (250) have also been shown to 
be beneficial in controlling asthma symptoms. 
10.2.5 Immunotherapy 
Immunotherapy is a new approach in which specific allergens are 
administered subcutaneously or sublingually for 5-6 years. At first the specific 
allergen is administered in small doses and then gradually increased to reach an 
optimal concentration. This enables the body to develop tolerance to the 
allergen, preventing a strong immune response when there is a subsequent 
encounter with the same allergen (22, 78, 113, 114). Immunotherapy is similar to 
34 
 
vaccination; the difference is that the former blunts the immune system and the 
latter provokes the immune system (33). This approach is directed towards the 
allergen and not the symptoms, and after 5-6 years of therapy patients have 
been shown to experience attenuated asthma-like symptoms. However, the 
disadvantage is that some patients develop severe anaphylactic responses 
during treatment (344). 
  11 Role of CD38 
11.1 Background 
CD38 is a 45 kDa transmembrane type II glycoprotein, ubiquitously 
expressed on the plasma membranes of cells (238). The CD38 gene with 70,776 
bases is located on chromosome 4 in the plus strand (4p15). The mRNA of CD38 
contains 1491 bases with 8 exons (NCBI).  The CD38 protein has 300 amino 
acids (UniProtKB). It has a short cytoplasmic N-terminal region with 20 amino 
acids and an extensive extra-cellular C-terminal region with 256 amino acids. 
The extracellular domain has multiple enzymatic functions such as ADP-ribosyl 
cyclase activity that converts β-NAD into cADPR, cADPR hydrolase activity that 
converts cADPR into ADP ribose and NAD+ glycohydralase activity that converts 
NAD+ into ADP-ribose (205). The first exon of CD38 transcript is responsible for 
producing the N-terminal and transmembrane portions of the protein while exons 
2-8 are encode the extra-cellular C-terminal region of the protein (249). CD38 
expressed on the plasma membrane of cells has many functions such as cell 
adhesion, calcium signaling and signal transduction (238).  
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Receptor activity of CD38 in leukocytes (T and B lymphocytes) and 
dendritic cells promotes activities such as adhesion and proliferation. CD38 plays 
a role in antigen priming in T lymphocytes and in proliferation of B lymphocytes 
by initiating upstream signaling cascades (222). In dendritic cells, CD38 plays a 
role in cell trafficking from peripheral tissues to lymph nodes and in antigen 
presentation to T lymphocytes (267, 268). In bone tissue, CD38 induces 
osteoclasts to increase bone absorption (311). In pancreas, it stimulates beta 
islet cells to secrete insulin. Impairment or loss of CD38 in these cells leads to 
type II diabetes mellitus (361).  
CD38 serves as a molecular marker in some disease states. It is used as 
a negative prognostic marker in chronic lymphocytic leukemia (CLL) (84). 
Presence of an increased number of circulating CD38+ B lymphocytes indicates 
that they are immature and in a proliferative stage. Typically, only B lymphocytes 
that are found in germinal centers of secondary lymphoid organs possess CD38 
(84). Once they come out of the germinal center and enter the marginal zone, 
they become CD38 negative. In CLL, because B cells proliferate rapidly, they 
escape normal maturation processes and enter the blood stream prematurely 
from lymph nodes. Therefore, the presence of CD38 on circulating B cells is an 
indicator of aberrant proliferation as seen in CLL. Similarly, increased expression 
of CD38 by regulatory T lymphocytes is also indicative of progressive CLL (219). 
In human immunodeficiency virus (HIV) infection, the amount of CD38 present on 
T lymphocytes correlates with disease progression (219).  
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11.2 Role of cyclic ADP-ribose (cADPR) 
In ASM cells, the enzymatic activity of CD38 is important because it 
produces cADPR which is involved in ASM contraction and AHR. The 
extracellular multi-enzymatic region of CD38 generates the potent second 
messenger cADPR required for the release of [Ca++]i from stores (204-208). 
There are many mechanisms proposed for the entry of extracellularly produced 
cADPR into the cytoplasm. Some of the suggested methods are via 
internalization by the plasma membrane (83), through connexin-43 channels 
(308), by a catalytically active channel created by 2 or 4 CD38 monomers (112) 
or by a nucleotide transporter (97). 
cADPR, after entering the cytoplasm, binds to an accessary protein FKBP 
12.6 and induces the ryanodine receptor to release Ca2++ into the cytoplasm from 
the sarco-endoplasmic reticulum, which serves as an intracellular calcium store 
(371). The released Ca++ in turn induces ryanodine receptors to release more 
calcium ions. This mechanism is referred to as “calcium induced calcium release 
(CICR)” (210) 
11.3. Calcium homeostasis 
Calcium concentrations within a cell are much lower (100-200 nM) than 
the extracellular compartment (1-2 mM) (96, 240). Normal calcium homeostasis 
in the intracellular compartment is strictly maintained. by the regulation of Ca++ 
“influx” from outside of the cell, “release” of Ca++ from intracellular stores and 
calcium re-uptake from cytoplasm into the sarco-endoplasmic reticulum through 
‘sarco-endoplasmic reticulum calcium ATPase’ (SERCA). Influx of calcium ions 
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occurs through various ion exchangers, voltage gated channels, calcium-release 
channels, second messengers and pumps. Other channels involved in 
maintaining [Ca++]i homeostasis are Store Operated Channels (SOC) and ORAI-
STEMI channels through a mechanism called Store Operated Calcium Entry 
(SOCE) (304, 310).  
11.4 Excitation-contraction coupling  
Agonists of subunit–Gq tagged GPCR such as histamine, bradykinin, 
cysteinyl leukotrienes, thrombin, serotonin and acetylcholine released from 
parasympathetic nerve terminals are known to regulate the calcium dynamics of 
ASM cells and their contractility through receptors in the ASM cell membrane 
(193). When ASM cells are excited they elicit a biphasic intracellular calcium 
response (234, 276). After stimulation, [Ca++]i  concentration shows a sharp 
elevation followed by a rapid fall but is still above the basal level and in a steady 
state. Altered intracellular calcium dynamics triggers many downstream cell 
signaling pathways. Elevated Ca++ binds to the protein calmodulin which 
activates Myosin Light Chain Kinase (MLCK). Activated MLCK, in turn 
phosphorylates the myosin and promotes its binding to actin. Sliding of actin-
myosin bridges causes the smooth muscle cells to contract (370). This explains 
the role CD38 plays in AHR (180). 
12. MicroRNAs 
12.1 Biogenesis and Mode of action 
MicroRNAs are produced endogenously in the nucleus. They are non-
coding, ~ 22 nucleotide long small RNAs involved in almost all cellular processes 
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including development, differentiation, metabolism, and organ functions as well 
as in many pathological processes such as inflammation, stress response, heart 
failures, renal failures, various forms of cancer and mental disorders (29). In 
mammals more than 50% of all protein coding genes are regulated by 
microRNAs. They exhibit a specific spatio-temporal expression pattern during 
environmental changes and developmental stages.  An individual microRNA can 
inhibit the expression of hundreds of genes, fine tune them at different levels and 
maintain the cellular network.  Aberrantly expressed microRNAs cause 
disturbances in the cellular network and lead to diseases. Up to now, about 1500 
microRNAs have been discovered in the human genome. Thus, microRNAs are 
emerging gene regulators, playing roles in a variety of disorders. Their 
expression and function are controlled through transcriptional and 
posttranscriptional mechanisms (29). Aberrant expression of microRNAs could 
be due to a single nucleotide polymorphism or nucleotide deletions either on their 
mature sequence or at the cleavage sites where RNA-lll endonucleases Drosha 
and Dicer act to cleave pri-microRNAs and pre-microRNAs, respectively (29).  
Pathogenic processes could also be initiated due to a polymorphism at the 
3’UTR of a target mRNA where microRNAs bind (297).  
12.2 MicroRNAs in asthma 
Accumulating evidence indicates that microRNAs play a crucial role in the 
development of asthma (21).  Changes in the expression levels of microRNAs 
can be identified in airway structural tissues such as epithelial and smooth 
muscle cells and serum from asthmatic patients (338). Altered microRNA levels 
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play a part in the pathogenesis of asthma. Based on several microRNA-target-
predicting algorithms, studies have proved that microRNAs control many 
signaling pathways involved in asthma pathogenesis such as expression of 
MMP, TGF-β signaling, inflammatory processes and NF-κB signaling (197, 338). 
Many studies in mouse models and with human cell cultures have revealed the 
role of microRNAs in asthma. A spontaneous development of asthma–like 
phenotype with inflammation and airway remodeling was observed in miR-155 
knockout mice (262). Another study showed that increased expression of miR-
126 is involved in TH2 inflammation and Toll-Like Receptor (TLR-4) activation in 
asthma (233). Chiba et. al. demonstrated that expression of miR-133a is reduced 
after IL-13 treatment of human bronchial smooth muscle cells (66). The above 
studies suggest that down-regulation of miR-155 or miR-133a and up-regulation 
of miR-126 may have a role in the pathogenesis of asthma.  
MiR-146a is expressed in a variety of cell types such as alveolar epithelial 
cells, bronchial epithelial cells and bronchial smooth muscle cells and alters the 
expression of IL-1-β-induced chemokines such as IL-8 and RANTES (273). Thus 
MiR-146a may have a role in the pathogenesis of asthma as well.  
Stimulation of human airway smooth muscle cells with IL-1β, IFN-γ and 
TNF-α down-regulates the expression of miR-25.  Inhibitors of miR-25 decreased 
the expression of RANTES and eotaxin but increased the expression of TNF-α. 
With KLF-4 as a target protein, which in turn is a potent inhibitor of smooth 
muscle-specific gene expression (197) and playing a role in regulating many pro-
inflammatory cytokines, miR-25 may play an important role in asthma 
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pathogenesis. MiR-708 plays a role in cell proliferation. In small cell lung 
carcinoma, highly expressed miR-708 down regulates the trans-membrane 
protein TMEM88 by directly binding to the 3’UTR of the transcript. Reduced level 
of TMEM88 protein, a negative regulator of the Wnt signaling pathway, induces 
cell proliferation in lung carcinoma (169). An anti-proliferative function of miR-708 
was observed in renal cell carcinoma, where it targets survivin, a member of the 
inhibitor of apoptotic protein (IAP) family (294). Survivin plays a role in 
proliferation and inhibiting apoptosis. It is highly expressed in embryonic tissues, 
cancerous cells and vascular smooth muscle cells during vascular injuries (294). 
Based on these studies, I hypothesize that miR-708 may have a potential role in 
ASM cell proliferation.  
12.3 MicroRNA therapy 
MicroRNAs can regulate multiple genes of redundant pathogenic 
pathways of a disease, and fine tune them to varying degrees to gain a favorable 
effect. Thus, unlike other therapeutics that target only one gene or protein, 
microRNA therapy can target multiple genes resulting in a more effective and 
potent outcome (338).  
Different approaches to microRNA therapy to reverse the disease 
condition include administration of synthetic mimics of specific microRNA or of 
viral vectors to replace the shortage of microRNAs that are down-regulated in the 
disease condition.  Another option is delivery of antagomirs of microRNAs or 
microRNA sponges, which compete for the same target as the microRNA of 
interest into cells to block the microRNAs that are over-expressed due to a 
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pathological condition. For example, tumor development in a mouse model of 
non-small cell lung cancer was reduced when mimic of let-7 was injected intra-
tumorally. Likewise, administration of an antagomir of miR-21 to a mouse model 
of gliomas decreased the activity of MMPs (118).  Yet another example is the 
complete regression of B lymphoid tumors by administration of  miR-21 to mice in 
vivo (237). 
Various chemical modifications such as, 2’-O-methyl, 2’-O-methoxyethyl, 
2’-fluoro, RNA with a phosphorothioate modification, modified nucleotide or 
locked nucleic acid, have been employed to increase the cellular uptake and 
stability of synthetic oligonucleotides (mimic of miRNA or inhibitors of miRNA). 
These chemically modified therapeutic nucleotides were conjugated with 
cholesterol at their 3’ end and wrapped in a lipid bilayer as lipid nanoparticles. 
These nanoparticles, when introduced into a tissue, fuse with the phospholipid 
bilayer of the cell membrane and gain entry to the cytoplasm. There they interact 
with endosomes at low pH and release therapeutic miRNAs intracellularly (44, 
49).  
In an experiment carried out to evaluate the efficacy of anti-miR-122  
therapy in hepatic C viral (HCV) infection, antagomir of miR-122 (5 mg/kg) with 
Locked Nucleic acids (LNA) modifications was injected intravenously into 
chimpanzees once a week for 12 weeks. After 2 weeks from the end of 
treatment, the viral titer was dramatically lower (400 times lower in serum and 
200 times lower in liver). In phase II trials in humans, administration of a 
chemically modified antagomir of miR-122 has shown successful results for HCV 
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infection. Recently, Regulus Therapeutics, Inc., announced that administration of 
chemically modified GalNac-conjugated anti-miR-122 at 2 mg/kg subcutaneously 
in patients with HCV as mono therapy reduced viral load by 4.1 log10 on day 29. 
They declared that the drug was safe, well-tolerated and has a promising 
pharmacokinetic profile.  
Thus far, miR-34, a deregulated microRNA in many cancers, is the only 
microRNA tested in clinical trials as replacement therapy. A synthetic miRNA 
mimic of miR-34 named MRX34 is in phase I clinical trials (Mirna Therapeutics) 
for liver cancer in humans.  Here MRX34 is incorporated into liposome as 
SMARTICLES (Marina Biotech) and delivered. 
Other approaches to deliver microRNA in vivo are (i) cationic liposomes 
(PU-PEI, DOTMA) (68) that have low immunogenicity and high cellular uptake 
but retain cytotoxicity and are non-biodegradable, (ii) neutral liposomes (siPORT, 
SLNs) (77, 325, 352) with low immunogenicity but have non-specific uptake and 
toxicity that accumulate in the lung, (iii) viral vectors that are stable and have high 
transfection efficiency but are highly immunogenic and toxic, (194) that have low 
immunogenicity but have poor cellular uptake with rapid degradation and renal 
clearance.  
While there are some draw backs and questions that remain unanswered 
about microRNA therapy such as their off-target effect, bio-stability, 
immunogenicity, toxicity and renal clearance, various reports have shown that 
the microRNA therapy can be well-tolerated in animals as well as in humans (39, 
192, 352) since microRNAs are endogenous unlike siRNAs which are synthetic.  
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13. Previous findings from our laboratory 
• Induction of CD38 expression by  pro-inflammatory cytokines in ASM 
cells (87) 
• Contribution of CD38 and cADPR to AHR (89). 
• Allergen sensitized Cd38 KO mice exhibit attenuated AHR relative to 
wild type mice (134).  
• ASM cells obtained from Cd38 KO mice showed reduced calcium 
responses compared to control mice in response to stimulation with 
spasmogens (89).  
• In the presence of 8-Br-cADPR, an antagonist of cADPR, HASM cells 
showed reduced calcium responses to contractile agonists (87). 
• Pro-inflammatory cytokine TNF-α-induced CD38 expression has 
transcriptional regulation through the MAP kinase and PI3 kinase 
pathway (180, 323). 
• Transcriptional regulation of CD38 occurs through transcription factors 
NF-κB and AP-1 (323).  
• Increased expression of CD38 in asthmatic HASM cells compared to 
NA-HASM cells (179). 
• Class 1A PI3 kinases increase CD38 expression in human ASM cells 
following exposure to TNF-α (180). 
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14. Significance of the study 
Asthma is a chronic respiratory disorder that is known for centuries. 
Despite considerable increase in knowledge regarding this disorder, several 
aspects about the pathogenic mechanism remain unclear and have hindered the 
development of completely effective treatment options or the prevention 
strategies. Currently, symptomatic treatment with corticosteroids is the first line of 
effective therapy for asthma, although a small number of patients are refractory 
to steroid therapy (256). Further, some asthmatic patients on therapy with other 
available drugs for asthma either do not respond well or show side effects. Thus, 
it is important to identify novel molecules that play a critical role in the 
pathogenesis of asthma and evaluate their function and regulation in order to 
define alternative targets for asthma therapy.  
In this context, previous studies from this laboratory have identified CD38 
on ASM cells as a potential asthma target. CD38, a transmembrane protein, is 
expressed in a variety of cells (191, 216, 224). ASM cells are known to play 
many important roles in the pathogenesis of asthma such as airway contractility, 
airway inflammation and remodeling (261). CD38 possesses multiple enzymatic 
activities. Its ADP-ribosyl-cyclase activity converts the nucleotide metabolite β-
NAD into cADPR, which is a potent intracellular Ca++ releaser (180). In HASM 
cells, elevated Ca++ in the intracellular compartment causes contraction of 
smooth muscle cells resulting in AHR, one of the cardinal features of asthma (87-
89, 133).   
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Previous studies from our laboratory indicate that signaling pathways 
associated with CD38 may provide novel therapeutic strategies in attenuating 
AHR and asthma. TNF-α and TH2 cytokines induce CD38 expression 
transcriptionally via transcription factors NF-κB and AP-1 and MAP Kinases (322, 
323). CD38 protein and transcripts are differentially induced in ASM cells derived 
from asthmatic patients compared to non-asthmatic patients (178). Since 
expression of the above transcription factors and MAP Kinases are comparable 
between asthmatic and non-asthmatic ASM cells, the differentially induced CD38 
expression could be due to post-transcriptional mechanisms which could 
potentially involve aberrantly regulated microRNAs in ASM cells during asthma.  
In this investigation, I explored the potential role of microRNA in the regulation on 
CD38 expression in HASM cells and in a mouse model of allergic asthma. 
Further, the effect of microRNA on the proliferative function of ASM cells was 
investigated. The findings of this study revealed novel regulatory pathways of 
CD38 expression and identified other asthma-related genes that contribute to the 
overall pathogenesis of asthma.  
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Background  
CD38, a membrane protein expressed in airway smooth muscle (ASM) 
cells, plays a role in cellular Ca2+ dynamics and ASM contractility. In human ASM 
(HASM) cells, TNF-α induces CD38 expression through activation of MAPKs, 
NF-κB, and AP-1, and its expression is differentially elevated in cells from 
asthmatic patients compared with cells from non-asthmatic subjects. The CD38 
3′-untranslated region (UTR) has targets for miR-140-3p. We hypothesized that 
miR-140-3p regulates CD38 expression in HASM cells by altering CD38 mRNA 
stability. Basal and TNF-α-induced expression of miR-140-3p was determined in 
non-asthmatic human ASM (NA-HASM) and asthmatic human ASM (AS-HASM) 
cells. NA-HASM and AS-HASM cells were transfected with control, miR-140-3p 
mimic, or miR-140-3p antagomirs, and CD38 expression and CD38 mRNA 
stability were determined. Luciferase reporter assays were used to determine 
miR-140-3p binding to the CD38 3′-UTR. Activation of p38, ERK, and JNK 
MAPKs, NF-κB, and AP-1 was determined in miR-140-3p mimic-transfected NA-
HASM. TNF-α attenuated miR-140-3p expression in NA-HASM and AS-HASM 
cells but at a greater magnitude in AS-HASM cells. CD38 mRNA expression was 
attenuated by miR-140-3p mimic at comparable magnitude in NA-HASM and AS-
HASM cells. Mutated miR-140-3p target on the CD38 3′-UTR reversed the 
inhibition of luciferase activity by miR-140-3p mimic. CD38 mRNA stability was 
unaltered by miR-140-3p mimic in NA-HASM or AS-HASM cells following arrest 
of transcription. TNF-α-induced activation of p38 MAPK and NF-κB was 
attenuated by miR-140-3p mimic. The findings indicate that miR-140-3p 
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modulates CD38 expression in HASM cells through direct binding to the CD38 3′-
UTR and indirect mechanisms involving activation of p38 MAPK and NF-κB. 
Furthermore, indirect mechanisms appear to play a major role in the regulation of 
CD38 expression. 
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Introduction 
CD38 is a cell surface protein expressed in a variety of mammalian cells, 
including airway smooth muscle (ASM) cells (350). CD38 possesses multiple 
enzymatic activities, with ADP-ribosyl cyclase activity generating cyclic ADP-
ribose (cADPR), a Ca 2+-mobilizing agent (158, 209). Past studies in our 
laboratory established that the CD38/cADPR pathway plays an important role in 
cellular Ca++ dynamics and ASM contractility (87, 89). In human ASM (HASM) 
cells, TNF-α induces CD38 expression through activation of the transcription 
factors NF-κB and AP-1 and MAPK kinases (322). Among the MAPKs, p38 and 
ERK MAPKs mediate TNF-α-induced CD38 expression through modulation of 
transcript stability (322). We recently reported that, in ASM cells from subjects 
with a history of asthma, TNF-α-induced CD38 expression was differentially 
elevated, although the mechanistic basis of this differential elevation was not 
clearly understood (178). 
MicroRNAs (miRNAs) are noncoding small RNAs emerging as 
posttranscriptional regulators in various biological processes, including 
inflammation; they can regulate expression of their target genes by destabilizing 
the transcripts or by translational repression (29). Accumulating evidence has 
proven that miRNAs are associated with various pathological conditions in 
humans. Recent studies have shed light on the role of miRNAs in airway 
disorders such as asthma, chronic obstructive pulmonary disorder, and idiopathic 
pulmonary fibrosis. Recent studies report a role for miR-21 in determining the T 
helper (Th) type 1 (Th1)/Th2 immune response to antigen, thus playing a role in 
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the pathogenesis of allergic asthma (220, 221). Other studies have attempted to 
determine the role of specific miRNAs in airway inflammation and allergic airway 
hyperresponsiveness (AHR). Studies of the roles of let-7 and miR-155 in IL-13 
signaling and the potential role of miR-133 in RhoA expression were among 
those that highlight the roles of miRNA in the pathogenesis of airway 
inflammatory disorders (66, 220, 221, 231). In the present study, bioinformatic 
tools were used to determine potential miRNA response elements in the 3′-
untranslated region (UTR) of the human CD38 gene. Expression of miR-140-3p, 
which came as a top hit in one of the target prediction algorithms, and its 
functional role in CD38 expression were determined in asthmatic ASM (AS-
HASM) and nonasthmatic ASM (NA-HASM) cells. We hypothesized that miR-
140-3p downregulates CD38 expression in HASM cells through 
posttranscriptional mechanisms. 
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Materials and methods 
Reagents. 
Tris-base, glucose, HEPES, and other chemicals were purchased from Sigma 
Chemical (St. Louis, MO), unless otherwise noted. Human recombinant TNF-α 
(rhTNF-α) was purchased from R & D Systems (Minneapolis, MN); HBSS and 
DMEM from GIBCO-BRL (Grand Island, NY); TRIzol, SuperScript III reverse 
transcriptase, NCode miRNA first-strand synthesis kit, Platinum SYBR Green 
quantitative PCR (q-PCR) mix, and Lipofectamine RNAiMax from Invitrogen Life 
Technologies (Carlsbad, CA); miRVana RNA isolation kit from Ambion Life 
Technologies (Carlsbad, CA); NE-PER nuclear/cytoplasmic extraction kit from 
Pierce (Rockford, IL); antibodies for MAPKs and NF-κB and lamin A/C, actin, α-
tubulin, MAPK kinase 3 (MKK3), the dual-specificity phosphatase MKP-1, and 
nuclear receptor-interacting protein (NRIP-1) from Cell Signaling Technology; 
TransAM ELISA kits (NF-κB and AP-1) from Active Motif (Carlsbad, CA); 
QuikChange Lightning Multi Site-Directed mutagenesis kit from Agilent 
Technologies (Santa Clara, CA); control (C.ele-miR-67), miR-140-3p mimic, and 
antagomir (hsa-miR-140-3p mature sequence 5′-
UACCACAGGGUAGAACCACGG-3′) oligonucleotides from Dharmacon 
(Lafayette, CO); and chemiluminescent substrate for horseradish peroxidase 
(HRP) from Millipore (Billerica, MA). 
HASM cell cultures and treatments. 
Procedures for isolation and culture of HASM cells are described elsewhere (87, 
178). Briefly, HASM cells were obtained from the laboratory of R. A. Panettieri, 
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Jr. The cells were from de-identified healthy donors (NA-HASM cells) and donors 
who died due to severe asthma (AS-HASM cells). All experiments were 
conducted in HASM cells in passage 4 or 5. In all the experiments, prior to 
exposure to TNF-α, the cells were growth-arrested for 48 h in arresting medium 
without serum, but in the presence of transferrin and insulin. In experiments to 
determine the expression of CD38 and miR-140-3p, the cells were exposed to 
vehicle (0.1% BSA in PBS) or 10 ng/ml rhTNF-α for 0–24 h. To determine CD38 
mRNA stability, the cells were exposed to TNF-α for 12 h and then washed to 
remove TNF-α before addition of actinomycin D (5 μg/ml) to arrest transcription. 
Total RNA was collected at 0, 6, 12, and 24 h after transcriptional arrest. Data 
are reported for only 0- and 24-h time points for brevity. In experiments to 
determine the activation of NF-κB and MAPKs, cells were exposed to rhTNF-α 
(10 ng/ml) for 1 h and 15 min, respectively. 
Extraction of total RNA and cDNA synthesis. 
Total RNA was extracted from HASM cells following the manufacturer's 
instructions (miRVana, Ambion). Briefly, HASM cells (5 × 104 – 2 × 105) were 
collected in sterile PBS and centrifuged, and the pellet was homogenized in a 
buffer provided in the kit. Column-eluted total RNA was quantified in a 
bioanalyzer (Agilent NanoDrop). To synthesize cDNA from small RNA, 200 ng of 
total RNA were polyadenylated, and cDNA was synthesized using NCode first-
strand synthesis kit according to the manufacturer's instructions. In parallel, 200 
ng of total RNA were used to synthesize cDNA from larger RNA using the 
SuperScript III reverse transcription kit. 
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Extraction of whole cell/nuclear lysates. 
Whole cell lysates were obtained by sonication of HASM cells (2–5 × 105) in lysis 
buffer (50 mM Tris, 100 mM NaCl, 50 mM NaF, 40 mM β-glycerol phosphate, 2 
mM EDTA, 0.2 mM Na3VO4, 1% Triton X-100, and protease inhibitor cocktail, pH 
7.4). Nuclear extracts were collected from HASM cells (5–6 × 105) using the NE-
PER cytoplasmic and nuclear extraction kit, according to the manufacturer's 
protocols. 
Transient transfection of HASM cells. 
HASM cells were plated into appropriate formats and cell number (2 × 105 
cells/well in a 6-well plate or 5 × 105 cells/plate in a 100-mm culture plate) 24 h 
prior to transfection. Transfection was performed using Lipofectamine RNAimax 
according to the manufacturer's instructions. Briefly, control (C.ele-miR-67), miR-
140-3p mimic, or miR-140-3p antagomir oligonucleotides were transfected at 5–
100 nM. Control oligonucleotide was transfected at 50 or 100 nM. 
q-PCR. 
To determine miR-140-3p expression, a forward primer specific to miR-140-3p 
and a universal primer targeting the poly (T) of the cDNA were used according to 
the manufacturer's instructions. Mammalian small nuclear RNA U6 was used for 
normalization of miR-140-3p expression. To determine CD38 expression, q-PCR 
was performed using Brilliant SYBR Green Master Mix, as described elsewhere 
(322). Cyclophilin was amplified as the housekeeping control. 
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Site-directed mutagenesis. 
Site-directed mutagenesis was performed in luciferase-CD38 3′-UTR reporter 
plasmids. CD38–3′-UTR (481 bases long; UGC genome browser) has a 
predicted miR-140-3p target site at 8 bases after the stop codon in the CD38 
mRNA. The first miR-140-3p target had a 7-base complementarity to the miR-
140-3p. A second target site with a 6-base complementarity to miR-140-3p was 
found 21 bases from the first target site. The first target site (mutated 1) or both 
target sites (mutated 1+2) were mutated to determine the selectivity of miR-140-
3p binding to these sites. The QuikChange Lightning Multi Site-Directed 
mutagenesis kit was used to mutate 4 bases (taGaGGa) at the first target site 
(CTGTGGT) or 3 bases (aGaGGa) at the second target site (TGTGGT) (Fig. 2A, 
top). Twenty bases flanking the target site with mutation were designed as 
primers for mutation. The primers for each mutagenesis were as follows: first 
target site mutation primer 
(TCTGAGATCTGAGCCAGTCGtaGaGGaTGTTTTAGCTCCTTGACTCC) and 
second target site mutation primer 
(TTTAGCTCCTTGACTCCTaGaGGaTTATGTCATCATACATGACTCAGC). Wild-
type and mutant plasmids were expanded in Escherichia coli and sequenced to 
confirm mutations. 
SDS-PAGE and Western blotting. 
Total protein (10 μg) was resolved in a 4–20% Tris·HCl SDS gel and 
electrophoretically transferred onto a polyvinylidene difluoride membrane. The 
blot was blocked in 5% skim milk solution in PBS containing 0.05% Tween 20 for 
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≥4 h. The blot was probed with relevant primary antibodies and then incubated 
with HRP-conjugated secondary antibodies. After washes in PBS containing 
0.05% Tween 20, the blots were treated with the chemiluminescent substrate for 
HRP and exposed to X-ray film for visualization of bands. 
ELISA. 
For determination of NF-κB or AP-1 activation, ELISA was performed according 
to the manufacturer's instructions (Activ Motif) and as previously described (178). 
Briefly, 3 μg of nuclear extracts from HASM cells were incubated in a multiwell 
plate coated with oligonucleotides carrying consensus NF-κB or AP-1 
sequences. Competitor oligonucleotide (20 pmol, 20× excess) was added to 
some reactions to determine the specificity of the binding. 
ADP-ribosyl cyclase assay. 
The ADP-ribosyl cyclase activity of HASM cell lysates was quantified by 
measurement of the reverse cyclase activity of CD38. HASM whole cell lysates 
containing 5 μg of total protein were incubated for 1 h at 37°C with or without 10 
mM nicotinamide in the presence of 0.45 mM cADPR. The reverse cyclase 
reaction was stopped by addition of 25 μl of 1 M HCl, vacuum-filtered through a 
0.45-μm protein-binding membrane (Immobilon, Millipore), and neutralized with 
15 μl of 2 M Tris-base. The filtrate was incubated with reagent mixture containing 
2 μM rezasurin, 0.76% (vol/vol) ethanol, 4 μM flavin mononucleotide, 40 μg/ml 
alcohol dehydrogenase, and 0.04 U/ml diaphorase in NaH2PO4/Na2HPO4 buffer, 
pH 6.8, at room temperature. Fluorescence was quantified (excitation at 544 nm 
and emission at 590 nm) in a fluorometer (FLUO star Galaxy, BMG 
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Biotechnologies), and the rate of fluorescence emission was calculated. The 
quantity of NAD generated in the reaction was calculated from a standard curve 
generated from known NAD. 
Data analysis. 
Each experiment was performed three to six times (NA-HASM or AS-HASM cells 
obtained from 3–6 donors were used). Values are means ± SE. Data were 
statistically analyzed by Student's t-test or one-way ANOVA (depending on the 
number of experimental groups analyzed) using GraphPad Prism software. 
Differences were considered significant at P ≤ 0.05. 
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Results 
Expression of miR-140-3p in HASM cells. 
HASM cells were exposed to vehicle (0.1% BSA in sterile PBS) or TNF-α (10 
ng/ml) for 24 h, and expression of miR-140-3p and CD38 mRNA was 
determined. In TNF-α-treated NA-HASM cells, miR-140-3p expression was 
marginally reduced compared with vehicle-treated cells (Fig. 1A). In TNF-α-
treated AS-HASM cells, miR-140-3p expression was significantly reduced 
compared with vehicle-treated cells (Fig. 1B). The basal miR-140-3p expression 
levels were comparable in NA-HASM and AS-HASM cells (Fig. 1C). Exposure to 
TNF-α for 24 h resulted in downregulation of miR-140-3p expression in NA-
HASM and AASM cells, but to a greater magnitude in AS-HASM cells (Fig. 1C). 
Exposure to IL-13, a Th2 cytokine with a critical role in asthma pathogenesis, did 
not alter miR-140-3p expression in either group of HASM cells (data not shown). 
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Fig. 1. Expression of miR-140-3p in vehicle-treated (C) and TNF-α-treated  
nonasthmatic airway smooth muscle (NA-HASM) and asthmatic airway 
smooth muscle (AS-HASM) cells. A: in the presence of TNF-α, miR-140-3p 
expression was marginally attenuated in NA-HASM cells compared with cells 
treated with vehicle (n = 5). B: in AS-HASM cells, TNF-α significantly attenuated 
miR-140-3p expression (n = 6). *P < 0.05. C: basal miR-140-3p expression levels 
were comparable between NA-HASM and AS-HASM cells. In the presence of 
TNF-α, miR-140-3p expression was significantly attenuated in AS-HASM cells 
compared with NA-HASM cells. *P < 0.05. (Data in A–C are from the same 
experiments.) D: when NA-HASM (NA) and AS-HASM (A) cells were exposed to 
TNF-α for 0–24 h, both showed attenuated miR-140-3p expression at 24 h, 
although reduction was statistically significant only in AS-HASM cells (n = 3). *P 
< 0.05. E: TNF-α produced a time-dependent increase in CD38 mRNA 
expression in NA-HASM and AS-HASM cells. Magnitude of CD38 induction in 
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AS-HASM cells was higher in AS-HASM cells, although differential increase was 
not statistically significant because of larger standard error in AS-HASM cells. 
 
In another set of experiments, miR-140-3p expression was determined at 
different times following exposure to TNF-α. Significant attenuation of miR-140-
3p expression was noted at 24 h of TNF-α exposure in AS-HASM cells compared 
with NA-HASM cells (Fig. 1D). TNF-α induced CD38 mRNA expression in a time-
dependent manner in NA-HASM and AS-HASM cells, with larger magnitudes of 
CD38 expression in AS-HASM cells, confirming our earlier findings (178) (Fig. 
1E). 
miR-140-3p mimic inhibits TNF-α-induced CD38 up-regulation in HASM 
cells. 
To determine the functional role of miR-140-3p in CD38 expression in HASM 
cells, we transfected NA-HASM and AS-HASM cells with miR-140-3p mimic or 
control oligonucleotides and determined the effects on CD38 mRNA expression 
and ADP-ribosyl cyclase activity. Transfection of NA-HASM cells with a range of 
miR-140-3p mimic oligonucleotides resulted in a concentration-dependent 
increase in miR-140-3p expression (Fig. 2A). In cells transfected with miR-140-
3p mimics, upregulation of TNF-α-induced CD38 mRNA was significantly 
attenuated in a concentration-dependent manner, although without a linear 
relationship to the mimic concentration (Fig. 2B). At higher concentrations of 
miR-140-3p mimic (20 and 50 nM), TNF-α-induced ADP-ribosyl cyclase activity 
was significantly reduced compared with the cells transfected with 50 nM control 
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oligonucleotide (Fig. 2C). At the optimal concentration (50 nM), miR-140-3p 
mimic transfection attenuated TNF-α-induced CD38 mRNA expression in NA-
HASM and AS-HASM cells to a similar magnitude (Fig. 2D). Transfection of NA-
HASM and AS-HASM cells with miR-140-3p mimic oligonucleotides also resulted 
in comparable inhibitory effects on TNF-α-induced ADP-ribosyl cyclase activity 
(Fig. 2E). Transfection of antagomirs for miR-140-3p did not alter basal or TNF-
α-induced ADP-ribosyl cyclase activity in either group of HASM cells (Fig. 2E). 
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Fig. 2. Inhibition of TNF-α-induced CD38 expression in HASM cells by miR-
140-3p mimic. Mimics of miR-140-3p (140 mimic) or antagomirs for the 
microRNA (miRNA) were transiently transfected into NA-HASM and AS-HASM 
cells, and CD38 mRNA expression and ADP-ribosyl cyclase activity were 
determined. A: transient transfection of NA-HASM cells with miR-140-3p mimic 
oligonucleotide resulted in a concentration-dependent increase in miR-140-3p 
expression (n = 3). B: transfection of miR-140-3p mimics in NA-HASM cells 
resulted in a concentration-dependent attenuation of TNF-α-induced CD38 
mRNA expression, although the relationship between mimic concentration and 
CD38 expression was not linear (n = 3). *P < 0.05, all concentrations vs. control 
oligonucleotide (Cont oligo). C: in NA-HASM cells transiently transfected with 
miR-140-3p mimic oligonucleotides, ADP-riboysl cyclase activity was significantly 
attenuated at higher concentrations of the mimic (n = 3). *P < 0.05 vs. Cont oligo. 
D: when NA-HASM and AS-HASM cells were transiently transfected with 50 nM 
control oligonucleotide or miR-140-3p mimic oligonucleotide, CD38 mRNA 
expression was comparably attenuated in both groups of cells (n = 2). *P < 0.05. 
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E: TNF-α-induced ADP-ribosyl cyclase activity was attenuated to a comparable 
magnitude in NA-HASM and AS-HASM cells in the presence of miR-140-3p 
mimic oligonucleotides (n = 3). Basal [control (C)] and TNF-α-induced (T) ADP-
ribosyl cyclase activities were unaltered in NA-HASM or AS-HASM cells 
transiently transfected with miR-140-3p antagomir oligonucleotides (n = 3). *P < 
0.05 vs. Control oligonucleotide (T). 
 
miR-140-3p targets the CD38 3′-UTR. 
To determine whether miR-140-3p brings about its effects through direct binding 
to the 3′-UTR of CD38, dual luciferase reporter assays were performed in human 
embryonic kidney (HEK)-293 or NIH 3T3 cells. Cotransfection of cells with miR-
140-3p mimic oligonucleotides and the wild-type Luc-CD38 3′-UTR resulted in a 
marginal 10–20% inhibition of luciferase activity in HEK-293 or NIH 3T3 cells. 
Site-directed mutation of the first miR-140-3p target on the CD38 3′-UTR partially 
reversed the inhibition by miR-140-3p mimic oligonucleotide in HEK-293 cells 
(Fig. 3A). When the luciferase reporter assay studies were repeated in NIH 3T3 
cells, site-directed mutation of the first miR-140-3p target completely reversed 
the luciferase inhibition by miR-140-3p mimic (Fig. 3B). Mutation of both miR-
140-3p targets on the CD38 3′-UTR resulted in elevated luciferase activity in the 
presence of miR-140-3p mimic oligonucleotides (Fig. 3B). To determine the 
effect of miR-140-3p mimic transfection on CD38 mRNA stability, NA-HASM and 
AS-HASM cells were transfected with 20 nM control oligonucleotide or miR-140-
3p mimic. At 12 h following TNF-α exposure (0 h), mimic-transfected NA-HASM 
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and AS-HASM cells showed attenuated CD38 mRNA levels compared with 
control oligonucleotide-transfected cells (Fig. 3C). There were no further 
reductions in CD38 mRNA levels in mimic-transfected cells at 6, 12, and 24 h in 
either group of HASM cells (Fig. 3C; 6- and 12-h data not shown). 
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Fig. 3. miR-140-3p targets the CD38 3′-untranslated region (UTR). Luciferase 
reporter assays were performed in Luc-CD38-3′-UTR constructs containing wild-
type or mutated (Mutated) target. A: 2 miR-140-3p targets on CD38 3′-UTR and 
mutations on each target (top). ORF, open reading frame. Bottom: in human 
embryonic kidney (HEK)-293 cells cotransfected with wild-type Luc-CD38-3′-UTR 
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and miR-140-3p mimic oligonucleotides, luciferase activity [relative light units 
(RLU)] was marginally reduced compared with cells cotransfected with 
scrambled-sequence oligonucleotides; in HEK-293 cells cotransfected with 
target-mutated Luc-CD38-3′-UTR and miR-140-3p mimic oligonucleotides, 
inhibition of luciferase activity was partially reversed (n = 3). B: in NIH 3T3 cells 
cotransfected with wild-type Luc-CD38-3′-UTR and miR-140-3p mimic 
oligonucleotides, luciferase activity was marginally reduced compared with cells 
cotransfected with scrambled-sequence oligonucleotides. When the first miR-
140-3p target on Luc-CD38-3′-UTR was mutated (mutated 1), inhibition of 
luciferase activity was completely reversed. When both miR-140-3p targets on 
Luc-CD38-3′-UTR were mutated (mutated 1+2), luciferase activity was 
significantly elevated in the presence of miR-140-3p mimic oligonucleotides (n = 
4). C: in NA-HASM and AS-HASM cells transfected with miR-140-3p mimic 
(mimic 140), CD38 mRNA levels were comparably attenuated at 0 h (NA-0 and 
A-0; following TNF-α removal and transcriptional arrest) compared with cells 
transfected with control oligonucleotides. There were no further reductions in 
CD38 mRNA levels at 6, 12, or 24 h (NA-24 and A-24) following transcriptional 
arrest in mimic-transfected cells of either group. *P < 0.05 vs. wild-type or 
mutated vector cotransfected with scramble oligonucleotide. **P < 0.05 vs. wild-
type vector cotransfected with miR-140-3p mimic oligonucleotide. ActD, 
actinomycin D. 
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miR-140-3p mimic attenuates activation of p38 MAPK in HASM cells. 
Results of the 3′-UTR luciferase reporter assay indicated that direct 
binding of miR-140-3p mimic on the 3′-UTR of CD38 only partially accounted for 
the inhibition of CD38 expression. We previously reported that the MAPKs 
mediate TNF-α-induced CD38 expression in HASM cells (322). Therefore, to 
determine whether changes in MAPK activation were involved in the miR-140-3p 
effect on CD38 expression, activation of p38, ERK, and JNK MAPKs was 
determined in HASM cells following transfection with miR-140-3p mimic 
oligonucleotides. Transfection with miR-140-3p mimic reduced the TNF-α-
induced p38 phosphorylation, with no significant changes in the expression of 
total p38 (Fig. 4, A and B). TNF-α-induced activation of ERK or JNK was not 
altered by transfection with miR-140-3p mimic (Fig. 4, C and D). Expression of 
MKK3, a Ser/Thr protein kinase upstream of p38 MAPK, was not altered in the 
presence of miR-140-3p mimic oligonucleotides (Fig. 4E). We also determined 
the expression of MKP-1, which is known to inactivate p38, ERK, and JNK 
MAPKs. Transfection of HASM cells with miR-140-3p antagomir or mimic 
oligonucleotides did not alter MKP-1 expression (Fig. 4F). 
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Fig. 4. miR-140-3p mimic attenuates activation of p38 MAPK in NA-HASM 
cells. TNF-α-induced activation of p38, ERK, and JNK MAPKs was determined 
in NA-HASM cells transiently transfected with 50 nM control oligonucleotides or 
miR-140-3p mimic oligonucleotide. A: representative Western blot showing 
marginally reduced TNF-α-induced p38 MAPK activation in miR-140-3p mimic 
transfection. Phos, phosphorylated. B: average relative densitometry 
measurement (n = 5) of Western blot showing marginally reduced p38 MAPK 
activation in miR-140-3p mimic-transfected NA-HASM cells. C and D: basal and 
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TNF-α-induced activation of ERK and JNK MAPKs was not altered in the 
presence of miR-140-3p mimics. Blots are representative of 5 independent 
experiments. E: expression of MAPK kinase 3 (MKK3), a kinase upstream of p38 
MAPK, was not altered by transient transfection with miR-140-3p mimic 
oligonucleotides. Blot is representative of 3 independent experiments. F: 
representative blot showing unaltered expression of MKP-1, a dual-specificity 
phosphatase, in HASM cells transfected with miR-140-3p antagomir or miR-140-
3p mimic oligonucleotides (n = 3). 
 
miR-140-3p mimic attenuates activation of NF-κB in HASM cells. 
We previously reported that the transcription factors NF-κB and AP-1 mediate 
TNF-α-induced CD38 expression in HASM cells (181, 322). Transient 
transfection of HASM cells with miR-140-3p mimic oligonucleotides marginally 
attenuated activation of the transcription factor NF-κB (Fig. 5, A and B). 
Transfection with miR-140-3p did not have a significant effect on TNF-α-induced 
AP-1 activation (Fig. 5C). Expression of NRIP was not altered by miR-140-3p 
mimic transfection in HASM cells (Fig. 5D). 
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Fig. 5. miR-140-3p mimic attenuates activation of transcription factor NF-κB 
in NA-HASM cells. TNF-α-induced activation of NF-κB was determined in NA-
HASM cells transiently transfected with 50 nM control oligonucleotide or miR-
140-3p mimic oligonucleotides. A: TNF-α-induced nuclear translocation of NF-κB 
C 
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(phosphorylated p65 subunit) was marginally attenuated in NA-HASM cells 
transfected with miR-140-3p mimic oligonucleotides. B: TNF-α-induced activation 
of NF-κB, measured as binding of p65 subunit to a consensus DNA motif 
[absorbance at 450 nm (Abs 450)], was marginally reduced in NAASM cells 
transfected with miR-140-3p mimic oligonucleotides (n = 5). C: TNF-α-induced 
activation of AP-1 (measured as binding of phosphorylated c-Jun to consensus 
DNA sequence) was unaltered in the presence of miR-140-3p mimic 
oligonucleotides (n = 4). D: expression of nuclear receptor-interacting protein 
(NRIP), which is associated with NF-κB activation in other cell systems, was not 
altered in HASM cells transfected with mimic 140 (n = 3). Blots (A and D) are 
representative of results from 3 independent experiments. C, vehicle; T, TNF-α. 
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Discussion 
This is the first report of the regulatory role of miR-140-3p in CD38 
expression in HASM cells. Our findings show that miR-140-3p expression is 
lower in HASM cells from donors with a history of severe asthma, in the presence 
of TNF-α. Our findings also indicate that the effects of miR-140-3p on CD38 
expression are mediated through direct binding of miRNA to the CD38 transcript 
and indirect mechanisms involving activation of p38 MAPK and NF-κB. The net 
result of the modest inhibition of activation of p38 and NF-κB by miR-140-3p 
transfection is the robust attenuation of CD38 expression in HASM cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNF-α 
NF-κB 
P38 MAPK 
CD38 
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Previous studies conducted in our laboratory established that TNF-α-
induced CD38 expression in HASM cells is mediated at the transcriptional and 
posttranscriptional levels (181, 322). The MAPKs ERK1/2 and p38 play a role in 
posttranscriptional regulation, whereas p38 and JNK MAPKs have a role in 
transcriptional regulation of the CD38 gene (322). One of the objectives of the 
current study was to determine the role of miR-140-3p in the regulation of CD38 
expression. Studies by other investigators revealed that specific miRNAs, such 
as miR-21 and miR-133a, contribute to the pathogenesis of airway inflammatory 
disorders (66, 221). Chiba et al. (66) showed that IL-13, a Th2 cytokine with a 
prominent role in allergic asthma, downregulates the expression of miR-133a. It 
is suggested that the downregulation of miR-133a leads to elevated RhoA, a 
procontractile protein in the ASM cells. CD38 contributes to the development of 
AHR in mouse models of asthma (133, 134). The CD38-null mouse developed 
significantly lower levels of airway responsiveness than the wild-type mouse in 
response to the contractile agonist methacholine (89). The CD38-null mouse also 
developed reduced AHR compared with the wild-type mouse following brief 
exposure to TNF-α or IL-13 (133, 134). Therefore, investigating the miRNAs that 
target CD38 gene expression in HASM cells may lead to an understanding of the 
signaling pathways involved in the pathogenesis of AHR and asthma. 
Multiple web-based target prediction algorithms [Target Scan 
(www.targetscan.org), miRWalk (www.ma.uni-heidelberg.de), and miRbase 
(www.mirbase.org)] were used to determine potential miRNA targets in the CD38 
3′-UTR. From the list of predicted miRNAs, miR-140-3p was chosen for further 
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investigation, because it has been reported as one of the highly expressed 
miRNAs in HASM cells (354). Furthermore, in HASM cells exposed to a mixture 
of inflammatory cytokines including TNF-α, there is significant downregulation of 
several miRNAs, including miR-140 and some miRNAs involved in the regulation 
of the smooth muscle phenotype (197). In earlier publications by other 
investigators, miR-140 has been reported as a cartilage-specific miRNA in 
mouse and zebrafish (329, 351). However, these reports were largely referring to 
miR-140-5p, one of the two mature miRNAs originating from the precursor miR-
140. In the present study, we focused on miR-140-3p and its role in regulation of 
CD38 expression. 
An altered miRNA expression profile has been reported in T cells obtained 
from patients with severe asthma, indicating that miRNAs are among the 
mechanisms involved in the cellular phenotypic changes observed in asthma 
(328). Attenuation of miR-140-3p expression in AS-HASM cells by TNF-α 
suggests that this miRNA may have a role in the asthmatic phenotype in ASM 
cells. The mechanisms involved in miR-140-3p downregulation by TNF-α in 
HASM cells are yet to be determined. Recent studies in human chondrocytes 
showed that the proximal upstream region of pri-miR-140 has functional 
response elements for chondrogenic transcription factors Sox5/Sox6/Sox9, 
indicating transcriptional regulation of miR-140-3p and miR-140-5p expressions 
(363). Different transcriptional regulators and epigenetic mechanisms such as 
DNA methylation may be involved in the altered miR-140-3p expression in AS-
HASM cells. The finding that miR-140-3p expression is attenuated to a larger 
75 
 
magnitude in AS-HASM cells in the presence of TNF-α suggests an anti-
inflammatory role for this miRNA. The potential anti-inflammatory role for miR-
140-3p is supported by previously reported findings of downregulated miR-140 
expression in whole lung lysate from rats exposed to cigarette smoke extract 
(167). We also found that IL-13, a Th2 cytokine with a major role in asthma, did 
not alter the expression levels of miR-140-3p in NA-HASM or AS-HASM cells 
(data not shown). These observations suggest that miR-140-3p may have a 
functional role selective to TNF-α signaling. TNF-α is a cytokine with a major role 
in the pathogenesis of asthma (4, 321). TNF-α expression is elevated in the 
airways of asthmatic patients, and some recent therapeutics for asthma target 
TNF-α and its receptors in lungs (34, 45, 160, 367).  Therefore, defining the role 
of miRNAs involved in the regulation of TNF-α-induced genes in ASM may have 
a therapeutic potential. Although TNF-α attenuates miR-140-3p expression to a 
greater magnitude in AS-HASM cells, it does not appear to solely contribute to 
the differential induction of CD38 expression by TNF-α that we reported in a 
recent study (178). 
Although the inhibitory effect of miR-140-3p mimic on luciferase activity 
was modest, mutation of both miR-140-3p target sites reversed the inhibition, 
indicating binding of the miRNA to the 3′-UTR of CD38. Since the 3′-UTR of the 
CD38 transcript possesses targets for other miRNAs as well, a significant effect 
on stability or translatability of the CD38 transcript may require multiple miRNAs. 
However, the significant inhibition of CD38 mRNA and protein expression by 
miR-140-3p mimic oligonucleotides suggests that additional mechanisms are 
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involved in miR-140-3p regulation of CD38 expression in HASM cells. In this 
context, we found that miR-140-3p mimic attenuated p38 MAPK activation with 
no apparent effects on ERK or JNK MAPKs, demonstrating the selectivity of miR-
140-3p for specific targets on cell signaling pathways in HASM cells. The 
marginal inhibitory effect of miR-140-3p mimic on p38 MAPK activation does not 
appear to be related to the upstream kinase MKK3 or the MAPK dual-specificity 
phosphatase. However, it remains to be determined whether other MAPK 
phosphatases with higher substrate specificity to p38 MAPK mediate the miR-
140-3p-mediated attenuation of p38 activation. 
The significant attenuation of TNF-α-induced CD38 mRNA expression by 
miR-140-3p mimic suggests that the regulation by miRNA may be through 
transcription of the CD38 gene in HASM cells. The transcription factors NF-κB 
and AP-1 mediate TNF-α-induced CD38 expression in HASM cells (181). The 
role of NF-κB signaling in airway inflammatory disorders has been demonstrated 
through in vitro studies and animal models (90, 318). For this reason and 
because of the availability of numerous synthetic inhibitors of NF-κB signaling, 
this pathway remains an attractive therapeutic target in airway inflammatory 
disorders such as asthma and chronic obstructive pulmonary disorder. Although 
the DNA binding activity of NF-κB was only marginally reduced by miR-140-3p 
mimic transfection, the reduction was a consistent finding in five independent 
experiments. Furthermore, a recent study reported attenuation of NF-κB 
activation by miR-140-3p in hepatocytes, primarily by targeting NRIP-1, a 
coactivator of NF-κB (316). This is an unlikely mechanism in HASM cells, since 
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NRIP-1 expression was unaltered in cells transfected with miR-140-3p. The 
results of CD38 mRNA stability also showed that, following transcription arrest, 
CD38 mRNA levels were maintained for up to 24 h. The expression levels of 
miR-140-3p remain high for up to 72 h following transfection. If the effects of 
miR-140-3p on CD38 transcript levels were due to binding to 3′-UTR target sites, 
we would have seen a significant decline in transcript levels following 
transcription arrest. A lack of correlation between miR-140-3p and CD38 
expression following TNF-α treatment strengthens the argument that miR-140-3p 
effects are largely indirect and time-dependent. Furthermore, overexpression of 
miR-140-3p causes a significant decline in CD38 transcript levels before arrest of 
transcription, with no further decline in transcript levels for up to 24 h, favoring a 
mechanism that involves indirect transcriptional regulation of CD38 expression in 
HASM cells. 
In summary, miR-140-3p regulates TNF-α-induced CD38 expression in 
HASM cells through direct interaction with the 3′-UTR of CD38 mRNA and 
indirect mechanisms involving activation of p38 MAPK and the transcription 
factor NF-κB. However, we cannot rule out other indirect mechanisms, such as 
competing endogenous RNAs (320), in the regulation of CD38 expression in 
HASM cells. Understanding the signaling pathways involved in miR-140-3p 
regulation of CD38 expression in HASM cells may reveal novel therapeutic 
targets for AHR and asthma. 
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Background  
The cell-surface protein CD38 mediates airway smooth muscle (ASM) 
contractility by generating cyclic ADP-ribose, a calcium-mobilizing molecule. In 
human ASM cells, TNF-α augments CD38 expression transcriptionally by NF-κB 
and AP-1 activation through inducing MAPK and PI3K signaling. CD38−/− mice 
develop attenuated airway hyperresponsiveness following allergen or cytokine 
challenge. The post-transcriptional regulation of CD38 expression in ASM is 
relatively less understood. In ASM, microRNAs (miRNAs) regulate inflammation, 
contractility, and hyperproliferation. The 3’ Untranslated Region (3’UTR) 
of CD38 has multiple miRNA binding sites, including a site for miR-708. MiR-708 
is known to regulate PI3K/AKT signaling and hyperproliferation of other cell 
types. We investigated miR-708 expression, its regulation of CD38 expression 
and the underlying mechanisms involved in such regulation in human ASM cells. 
Growth-arrested human ASM cells from asthmatic and non-asthmatic 
donors were used. MiRNA and mRNA expression were measured by quantitative 
real-time PCR. CD38 enzymatic activity was measured by a reverse cyclase 
assay. Total and phosphorylated MAPKs and PI3K/AKT as well as enzymes that 
regulate their activation were determined by Western blot analysis of cell lysates 
following miRNA transfection and TNF-α stimulation. Dual luciferase reporter 
assays were performed to determine whether miR-708 binds directly 
to CD38 3’UTR to alter gene expression. 
Using target prediction algorithms, we identified several miRNAs with 
potential CD38 3’UTR target sites and determined miR-708 as a potential 
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candidate for regulation of CD38 expression based on its expression and 
regulation by TNF-α. TNF-α caused a decrease in miR-708 expression in cells 
from non-asthmatics while it increased miR-708 expression in cells from 
asthmatics. Dual luciferase reporter assays in NIH-3 T3 cells revealed regulation 
of expression by direct binding of miR-708 to CD38 3’UTR. In ASM cells, miR-
708 decreased CD38 expression by decreasing phosphorylation of JNK MAPK 
and AKT. These effects were associated with increased expression of MKP-1, a 
MAP kinase phosphatase and PTEN, a phosphatase that terminates PI3 kinase 
signaling. 
In human ASM cells, miR-708 regulates the TNF-α-induced-
CD38 expression directly by binding to 3’UTR and indirectly by regulating JNK 
MAPK and PI3K/AKT signaling and has the potential to control airway 
inflammation, ASM contractility and proliferation. 
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Introduction 
The cell-surface protein CD38 mediates calcium signaling in airway smooth 
muscle (ASM) and innate immune responses (268). The ADP-ribosyl cyclase 
activity associated with CD38 converts β-nicotinamide adenine dinucleotide (β-
NAD) to cyclic adenosine diphosphoribose (cADPR) and adenosine 
diphosphoribose (ADPR) (205). In previous investigations in ASM, we showed 
that cADPR mediates calcium release from the sarcoplasmic reticulum and 
promotes contractility (87, 88). Furthermore, CD38−/− mice exhibit attenuated 
methacholine responsiveness and airway hyperresponsiveness (AHR) following 
allergen sensitization and challenge as well as after intranasal IL-13 challenge 
(89, 120, 134). ASM cells obtained from CD38−/− mice exhibit attenuated 
intracellular calcium responses to contractile agonists relative to cells obtained 
from wild-type mice (89). These observations indicate a prominent role 
of CD38 in AHR, a cardinal feature of asthma in humans. 
The transcriptional regulation of CD38 in ASM involves the transcription factors 
NF-κB and AP-1 and signal transduction mechanisms involving activation of MAP 
kinases and PI3 kinase (179, 322). CD38 is ubiquitously expressed in many cell 
types in addition to ASM cells and its expression is augmented by inflammatory 
and Th2 cytokines including TNF-α and IL-13 (87),(24) (2, 67, 93, 116, 186, 196). 
While the transcriptional regulation of CD38 expression has been thoroughly 
investigated in mammalian cells, there is a paucity of information regarding post-
transcriptional regulation of its expression. In this regard, we recently reported 
evidence for such regulation involving the microRNA (miRNA) miR-140-3p (177). 
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In human ASM cells, human recombinant TNF-α-(rh-TNF-α)-
induced CD38 expression is attenuated by miR-140-3p through both direct 
binding to the 3’ Untranslated Region (3’UTR) of CD38 as well as indirect 
mechanisms involving activation of p38 MAP kinase and the transcription factor 
NF-κB. CD38 3’UTR is ~481b long and has multiple miRNA binding sites, 
including a site for miR-708. Prior studies have revealed a prominent regulatory 
role of miR-708 in the expression of phosphatase and tensin homolog (PTEN), 
which in turn regulates PI3 kinase signaling through activation of AKT(340). In 
other cell types, PI3 kinase/AKT signaling regulates expression of target genes 
by activating the proinflammatory transcription factor NF-κB (215). An effect of 
miR-708 on PTEN expression is expected to profoundly affect cytokine-
induced CD38 expression in ASM cells by modulating PI3 kinase signaling. In 
ASM cells obtained from asthmatics, rh-TNF-α induces significantly 
greater CD38 expression compared to its expression in cells from non-
asthmatics(178). In this study, we investigated the expression of miR-708, its 
potential additive role with miR-140-3p in the regulation of CD38 expression and 
the underlying mechanisms involved in such regulation in human ASM cells. We 
also examined miR-708 expression and its effects on CD38 expression in ASM 
cells obtained from asthmatics to determine whether the augmented cytokine-
mediated CD38 expression stems from altered regulation through miR-708. 
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Materials and methods 
Reagents 
DMEM was from GIBCO-BRL (Grand Island, NY); rh-TNF-α was from R&D 
Systems (Minneapolis, MN); TRIzol, SuperScript III reverse transcriptase, NCode 
miRNA first-strand synthesis kit, Platinum SYBR Green quantitative PCR (q-
PCR) mix, Opti-MEM® reduced serum medium and Lipofectamine® RNAiMax 
transfection reagent were from Invitrogen Life Technologies (Carlsbad, CA); 
Brilliant lll Ultra-Fast SYBR Green q-PCR Master Mix from Agilent Technologies, 
Inc (Santa Clara CA); Fugene HD transfection reagent was from Roche 
Diagnostics (Indianapolis, IN); QuikChange Lightning Multi Site-Directed 
mutagenesis kit was from Agilent Technologies, Inc (Santa Clara, CA); control 
oligo (scrambled sequence mimic), miR-708 mimic (mature miR-708 sequence: 
5’-AAGGAGCUUACAAUCUAGCUGGG-3’), and antagomir oligonucleotides 
were from Dharmacon (Lafayette, CO); Dual Luciferase Reporter Assay System 
was from Promega (San Luis Obispo, CA); NIH-3 T3 cells were from ATCC 
(#CRL-1658, Manassas, VA); chemiluminescent substrate for horseradish 
peroxidase (HRP) was from Millipore (Billerica, MA); rabbit primary antibodies 
against major MAPK family, PTEN, AKT2, AKT and β-actin as well as anti-rabbit 
secondary antibody were from Cell Signaling Technology (Danvers, MA); mouse 
primary antibodies for MKP-1, α-actin and goat-anti mouse antibodies were from 
Santa Cruz Biotechnology (Dallas, TX). Tris-base, glucose, HEPES and other 
chemicals were from Sigma Chemical Co. (St. Louis, MO) unless otherwise 
mentioned. 
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Culture and transfection of HASM cells 
Isolation, culture and maintenance of HASM cells was carried out as described in 
our previous publications (87, 178, 323)  Briefly, HASM cells obtained from 
unidentified healthy donors or from fatal asthmatics were maintained in culture 
and used until the smooth muscle phenotype is sustained (2–5 passages). 
DMEM supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin, and 0.25 g/ml amphotericin B was used to grow the HASM cells up 
to 80% confluency. Rh-TNF-α (10 ng/ml) was used to induce the expression of 
CD38 in HASM cells while control cells were treated with 0.1% BSA in PBS. 
Since human cells used in this study were obtained from unidentified donors, it is 
considered Exempt under National Institutes of Health guidelines. Drs. Panettieri 
and Kannan have Institutional Review Board approval for the use of these cells in 
the study. 
Transient transfection of primary HASM cells with miR-708 mimic, 
antagomir or scrambled sequence mimic at 10–100 nM was carried out in the 
presence of Lipofectamine® RNAiMax transfection reagent. Reduced serum 
Opti-MEM® medium was used as a base to prepare the transfection complex 
containing Lipofectamine and the oligonucleotides. After 20 min of incubation at 
room temperature the transfection complex was gently dropped on to the cell 
suspension (1.5-2.0 × 105 cells/well in 24 well plates or 2.5-3.0 × 105 cells/well in 
6 well plates) which was seeded few minutes (<3 min) prior to the addition of 
transfection complex. Transfected cells were incubated at 37°C for 24 h, growth 
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arrested for 24 h, exposed to rh-TNF-α for another 24 h before isolation of total 
RNA or total protein. 
Total RNA isolation 
PureLink and mirVana RNA isolation kits (Ambion Life Technologies, Carlsbad, 
CA) were used to isolate total large RNA and small RNA, respectively, according 
to the manufacturer’s instruction. 
cDNA synthesis and quantitative q-PCR 
NCode™ miRNA First-Strand-cDNA synthesis kit was used to synthesize cDNA 
followed by q-PCR for miRNAs using the Platinum q-PCR Kit according to the 
manufacturer’s instruction. Briefly, expression of miR-708 at constitutive levels 
and after induction with rh-TNF-α was measured by q-PCR after poly-
adenylation. Whole miR-708 sequence was employed as a specific forward 
primer and universal q-PCR primer was used as a reverse primer. Mammalian 
small nuclear RNA U6, a spliceosomal RNA, served as a control housekeeping 
gene. To measure changes in the expression of CD38 (178, 322) and JNK at 
transcript levels (following miR-708 mimic or scrambled sequence mimic 
transfection), q-PCR was performed using Brilliant SYBR Green Master Mix. 
Primers for JNK were selected using Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and performed in the Stratagene 
Mx3000p q-PCR system, under the following conditions: 1 cycle of 95°C for 5-
min segment, 40 cycles of 95°C for 30 s, 59°C for 30 s, 72°C for 45 s, and a final 
1 cycle of 95°C for 1 min, 59°C for 30s and 95°C for 30s (JNK forward primer 5’-
CACCACCAAAGATCCCTGACA-3’; JNK reverse primer 5’-
87 
 
CTGTGCTAAAGGAGAGGGCT-3’). Expression level of cyclophilin was used to 
normalize the expressions of CD38 and JNK. 
mRNA stability 
HASM cells were transfected with miR-708 mimic or scrambled sequence mimic. 
After 24 h, transfection medium was replaced with growth-arrest medium for 
24 h. Cells were then exposed to rh-TNF-α for 12 h in fresh growth arrest 
medium which was replaced with fresh growth arrest medium containing 
actinomycin D (5 μg/ml) to inhibit transcription. At different time points (0, 6, 12 
and 24 h), cells were collected for isolation of total RNA to evaluate the rate of 
decay of CD38 transcript by q-PCR. 
Western blot 
Twenty four hours after transfection of ASM cells with miRNA, cell growth was 
arrested for 24 h (with serum-free media containing transferrin and insulin) 
followed by treatment with rh-TNF-α for an additional 24 h. Cells were collected 
in the lysis buffer (50 mM Tris, 100 mM NaCl, 50 mM NaF, 40 mM β-glycerol 
phosphate, 2 mM EDTA, 0.2 mM Na3VO4, 1% Triton X-100, and protease 
inhibitor cocktail, pH 7.4), lysed by sonication and total protein concentration in 
the lysates estimated by Bradford assay (Bio-Rad Laboratories, Inc, Hercules, 
CA). Equal amounts of total protein (5–15 μg) were separated by SDS-PAGE (4-
20% gradient gels), transferred onto a PVDF membrane and blocked overnight in 
5% skim milk in PBS containing 0.05% Tween 20 (PBST) at 4°C. Incubation of 
membranes with primary antibodies was carried out in 1% skim milk in PBST at 
4°C overnight. After three 5-minute washes with PBST, membranes were 
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incubated with HRP-conjugated secondary antibodies in 1% milk for 1 h at room 
temperature. Primary rabbit antibodies against all major MAPKs, β-actin, PTEN, 
Pan AKT and AKT2 were used at a dilution of 1:1000 except antibodies to detect 
p38 and phospho-p38 which were used at a dilution of 1:500. Primary mouse 
antibodies (smooth muscle-specific α-actin and MKP-1) were used at a dilution of 
1:700. Anti-rabbit secondary antibodies were used at a dilution of 1:5000, while 
goat anti-mouse secondary antibodies were used at a dilution of 1:4000. To 
determine the activation of MAPKs and AKT following miR-708 transfection, cells 
were collected at 20 min or 2 h respectively after treatment with rh-TNF-α and 
lysed. After electrophoresis, same membranes were probed for phosphorylated 
and total protein expression, stripping membranes (Restore Plus Western Blot 
Stripping Buffer [Thermo Fisher Scientific Co., Pittsburgh], 30 min) between 
blots. Intensity of protein bands was measured using ImageJ image analysis 
software and the level of expression of phosphorylated protein relative to total 
protein was considered as a measure of activation. In the case of MKP-1, PTEN 
and total MAP kinase protein expression, cells were collected 24 h after 
stimulation with rh-TNF-α and changes in expression level relative to loading 
control (smooth muscle specific α-actin or β- actin) were measured. 
Reverse ADP-ribosyl cyclase assay 
The enzymatic function of CD38 was quantified by reverse cyclase assay as 
described in our earlier publication (178). Briefly, equal amount of (5 -15 μg) total 
proteins in human ASM (HASM) cell lysates were incubated at 37°C for 1 h with 
cADPR (0.45 mM) in the presence or absence of nicotinamide (10 mM). The 
89 
 
enzymatic reaction was terminated by adding 25 μl of 1 M HCl, and contents 
were vacuum filtered (0.45 μm, Immobilon, Millipore), neutralized (15 μl of 2 M 
Tris-base), and incubated at room temperature with a mixture of the following 
reagents: rezasurin (2 μM), ethanol, flavin mononucleotide (4 μM), alcohol 
dehydrogenase (40 μg/ml) and diaphorase (0.04 U/ml) in phosphate buffer 
(Na2HPO4/NaH2PO4). FLUO star Galaxy fluorometer was used to quantify the 
rate of fluorescence emitted at 590 nm which is proportionate to the amount of 
NAD generated by the CD38 present in 5–15 μg of total protein. 
Mutation of miR-708 target site and dual luciferase reporter assay 
Location of miR-708 target site at the 3’UTR of CD38 transcript is 21 bases away 
from the stop codon. Mutation of four bases (ctCgCCg) at the target site 
(AGCTCCT) specific for miR-708 was achieved using the QuikChange Lightning 
Multi Site-Directed mutagenesis kit. The primer sequence designed for the 
mutation consists of target sequence and 14 bases flanking the target sequence 
(5’-GCTGTGGTTGTTTTCTCGCCGTGACTCCTTGTGGT-3’). XL10-GOLD Ultra 
competent E. coli was used to expand the wild-type and mutant plasmids. NIH-
3 T3 cells seeded in 24 well plates (1.5-2.0 × 105 cells/well) were co-transfected 
with miR-708 mimic or scrambled sequence mimic (50 nM), wild-type (or 
mutated) firefly Luc-CD38-3’UTR-reporter plasmid (200 ng/well) and Renilla 
luciferase plasmid (control) (30 ng/well), in culture medium (Opti-MEM® reduced 
serum medium; 100 μl), facilitated by Fugene HD transfection reagent (1 μl/well). 
After 24 h, cells were collected in lysis buffer and luciferase activity in triplicate 
samples for each condition was measured with a luminometer according to the 
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manufacturer’s recommendation (Synergy 2 microplate reader, BioTek, 
Winooski, VT). Renilla luciferase activity was used to normalize the firefly 
luciferase activity. 
Statistical analysis 
HASM cells obtained from 3–8 different donors were used. Values represent 
means ± SEM. Data were analyzed for statistical significance by Student’s t-test 
or one-way ANOVA (depending on the number of experimental groups analyzed) 
using GraphPad Prism 6 Software. Differences were considered significant at 
p < 0.05. 
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Results 
Differential expression of miR-708 in HASM cells 
In order to investigate the potential regulation of CD38 expression by multiple 
miRNAs, we first analyzed the CD38 3’UTR for miRNA binding sites using target 
prediction algorithms. MiRNAs miR-1272, miR-548, miR-208a, miR-1298, miR-
708 and miR140-3p were predicted to bind to the CD383’UTR with high context 
score. Expression levels of these miRNAs in HASM cells were evaluated by q-
PCR. As co-expression of miRNA(s) along with its target gene transcript is 
required for regulation, using a cycle threshold (ct) cut-off, miRNAs with ct values 
above 34 in HASM cells were filtered out (Figure 1A). Other miRNAs (miR-708 
and miR140-3p) which showed ct values ranging from 20–30 (Figure 1A) were 
selected for further studies. 
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Figure 1. Expression of miR-708 in rh-TNF-α-treated ASM cells. A:Analysis of 
miRNAs that are predicted to target CD38 by q-PCR. Expression levels of these 
miRNAs in HASM cells with and without TNF-α treatment were normalized with 
small nuclear RNA U6. miRNAs with ct values above and below 34 in HASM 
cells are indicated by the horizontal line (n = 3–4 donors). B and C: miR-708 
expression in HASM cells from non-asthmatics (NA-HASM) and asthmatics (AS-
HASM), respectively. Rh-TNF-α produced a significant reduction in miR-708 
expression in growth-arrested NA-HASM cells compared with cells treated with 
vehicle (n = 8 donors), while it produced a significant increase in its expression in 
1
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C
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AS-HASM cells (n = 6 donors). D: miR-708 expression in AS-HASM cells is 
higher than in NA-HASM cells both under vehicle and TNF-α-treated conditions 
(3–5 donors/group). Values are shown as mean ± SEM. C-vehicle-treated cells 
(0.1% BSA); T- rh-TNF-α (10 ng/ml) treated cells. 
 
To evaluate the expression of miR-708 in HASM cells obtained from non-
asthmatic and asthmatic donors in the presence of rh-TNF-α, q-PCR was 
performed. In non-asthmatic HASM (NA-HASM) cells, rh-TNF-α produced a 
significant (p < 0.0001) reduction in the expression of miR-708 (Figure 1B) 
compared to expression in unstimulated (vehicle-treated) cells. In contrast, rh-
TNF-α exposure significantly increased the expression of miR-708 (p = 0.0098) in 
asthmatic-HASM (AS-HASM) cells (Figure 1C). Further, expression of miR-708 
in AS-HASM cells was found to be higher in vehicle treated (~2-fold) and rh-TNF-
α treated (>10-fold) cells when compared to NA-HASM cells (Figure 1D). 
miR-708 inhibits CD38 expression and its enzymatic activity in HASM cells 
To examine whether miR-708 alters the expression level of CD38, NA-HASM 
cells were transiently transfected with different concentrations (10nM, 50nM and 
100nM) of miR-708 mimic. Over-expression of miR-708 mimic at 50 nM and 100 
nM concentrations significantly decreased CD38 transcript level (Figure 2A). 
This finding was further confirmed in AS-HASM where miR-708 mimic at 50 nM 
significantly inhibited CD38 transcript level relative to the scrambled sequence 
mimic (Figure 2B). Further, transfection of AS-HASM cells and NA-HASM cells 
with miR-708 at a concentration of 50 nM decreased the enzymatic activity of 
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CD38 measured by ADP-ribosyl cyclase assay (Figure 2C). To establish the 
specificity of the inhibitory effect of endogenous miR-708 on CD38 expression, 
NA-HASM cells were transfected with miR-708 mimic, scrambled sequence 
mimic or the antagomir of miR-708 mimic. Rh-TNF-α-induced CD38 expression 
following miR-708-antagomir transfection was similar to the expression in cells 
transfected with scrambled sequence mimic (Figure 2D). 
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Figure 2.  miR-708 inhibitsCD38expression in HASM cells. A: NA-HASM cells 
were transfected with different concentrations of miR-708 mimic (mimic) or 
scrambled sequence mimic (scr), followed by exposure to 10 ng/ml rh-TNF-α. 
CD38 transcript levels were measured by q-PCR. Results are shown as % CD38 
C
D
96 
 
mRNA relative to scrambled sequence mimic (scr) transfection. Significant 
inhibition of CD38 expression was observed following transfection of miR-708 
mimic at concentrations ≥ 50 nM (n = 3–5 donors).B: CD38 transcript levels 
following transfection with miR-708 mimic (50 nM) or scrambled sequence mimic 
in AS-HASM cells. Note significant attenuation of CD38 expression by miR-708 
mimic transfection (n = 3 donors); C: ADP-ribosyl cyclase activity in AS-HASM 
(AS) and NA-HASM (NA) cells following transfection with miR-708 mimic or 
scrambled sequence mimic and exposure to rh-TNF-α (MT and ST, respectively, 
(n = 3 donors). Note significant attenuation of enzyme activity in cells from AS-
HASM and NA-HASM after transfection with miR-708 mimic. D: CD38 transcript 
levels in NA-HASM cells following transfection with miR-708 mimic (50 nM), 
scrambled sequence mimic or antagomir for the miRNA (ant-mir) (n = 3 donors). 
Note the lack of inhibition of CD38 expression in cells transfected with ant-miR. 
Data represent mean ± SEM. 
 
Our previous studies have identified a role for miR-140-3p in the regulation of 
cytokine-induced CD38 gene expression and enzyme activity independent of 
miR-708(177). Since the target sites of these miRNAs are closely situated in the 
3’UTR of CD38 transcript (see Figure 3A), we examined whether transfection of 
HASM cells with both miR-140-3p and miR-708 would amplify the inhibitory effect 
on enzymatic activity of CD38. Co-transfection of HASM cell with miR-140-3p 
and miR-708 at 50 nM and 100 nM (equimolar concentrations) significantly 
inhibited CD38 enzymatic activity relative to cells transfected with scrambled 
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sequence mimic. However there was no evidence of an additive effect 
(Figure 4).  
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Figure 3. Interaction of miR-708 with the 3’UTR of CD38.  A: Predicted 
binding sites for miR-708 and miR-140-3p in 3’UTR of CD38. Shown are the 
mutated bases in the miR-708 target site of the 3’UTR ofCD38. B: Relative 
luciferase activity in NIH-3 T3 cells co-transfected with reporter plasmid and 
different concentrations of miR-708 mimic (mimic) or scrambled sequence mimic 
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(scr) at the highest concentration (n = 3, experiments in triplicate). Note 
significant reduction in luciferase activity following transfection with miR-708 
mimic at all concentrations. C: Relative luciferase activity in cells co-transfected 
with reporter plasmid containing either wild-type (wild) or mutant 
(mut) CD38 3’UTR followed by transfection with 50 nM of miR-708 mimic (mimic) 
or scrambled sequence mimic (scr) (n = 3, experiments in triplicate). Note no 
inhibition of luciferase activity in cells co-transfected with mutant CD38 3’UTR. D: 
CD38 mRNA stability measured in growth-arrested HASM cells. Cells were 
transfected with 50 nM miR-708 and exposed to rh-TNF-α in the presence of 
actinomycin D. At time points indicated, CD38 transcript levels were quantified by 
q-PCR (n = 2–5 donors). Graph shows plots of non-linear regression of mRNA 
decay over time for NA-HASM and AS-HASM cells, with the dotted lines 
indicating the best fit. Values are means ± SEM for results shown. 
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Figure 4. Effect of miR-708 in combination with miR-140-3p on ADP-ribosyl 
cyclase activity in NA-HASM cells. Cells (n = 3 donors) were co-transfected 
with equimolar concentrations of miR-708 and miR-140-3p, miR-708 mimic alone 
or the corresponding control scrambled sequence mimic at the indicated 
concentrations followed by exposure to 10 ng/ml rh-TNF-α (T) and measurement 
of ADP-ribosyl cyclase activity. Data represents mean ± SEM. Note that no 
additive effect was observed in cells transfected with equimolar concentrations of 
miR-708 and miR-140-3p relative to miR-708 alone. 
 
miR-708 directly binds to 3’UTR of CD38 
MiRNAs can inhibit gene expression directly by binding to the target gene at the 
3’UTR or indirectly by inhibiting multiple components in the signaling pathway 
(30, 244). We first examined whether miR-708 regulates the expression of CD38 
by directly binding to its 3’UTR by performing dual luciferase reporter assays in a 
heterologous cell system (NIH-3 T3 cells). Four bases in the target sequence on 
the CD38 3’UTR were mutated to establish specificity of miR-708 target binding 
(Figure 3A). A significant reduction in relative luciferase activity was noted when 
miR-708 mimic and reporter plasmid were co-transfected compared to co-
transfection with a scrambled sequence mimic (Figure 3B). Mutation of four 
bases in the target sequence on the CD38 3’UTR reversed the inhibitory effect of 
miR-708 on luciferase activity confirming the specificity of its target binding at the 
3’UTR of CD38 (Figure 3C). To examine whether this binding leads to mRNA 
degradation, CD38 mRNA stability was measured in HASM cells transfected with 
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miR-708 mimic or scrambled sequence mimic and exposed to rh-TNF-α followed 
by actinomycin D for transcriptional arrest. For analysis of mRNA stability, the 
amount of CD38 mRNA remaining at each time point up to 24 h relative to 0 h 
was determined by q-PCR using the 2-ΔΔCt calculation method and plotting 
against time. Nonlinear regression analysis of biological replicate samples was 
fitted using one-phase decay kinetics (GraphPad Prism 6). In NA- and AS-ASM 
cells transfected with miR-708 mimic or the scrambled sequence mimic, there 
was comparable decay in CD38 mRNA content, with half-life ranging from 16–
32 h (Figure 3D). 
Transcriptional regulation of CD38 expression by miR-708 
In prior studies, we reported that cytokine-induced changes in CD38 expression 
in HASM cells involve activation of MAP kinases and PI3 kinases. Among the 
MAP kinases, p38 and JNK MAP kinases were found to regulate expression 
transcriptionally while ERK MAP kinase was involved in regulation post-
transcriptionally through transcript stability (322). In this study, we examined the 
effect of miR-708 transfection following TNF-α exposure (20 min) on levels of 
total MAP kinase protein as well as phosphorylated (activated) protein in order to 
determine whether decreased MAP kinase activation is an underlying 
mechanism in the regulation of CD38 expression. Cells were transfected with 
miR-708 mimic or its scrambled sequence mimic, exposed to rh-TNF-α for 24 h 
and expression levels of the MAP kinases determined by Western blot analysis 
of cell lysates. Transfection of HASM cells with miR-708 mimic had little effect on 
levels of phosphorylated or total ERK and p38 (Figure 5). A significant reduction, 
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however, was noted in the level of phosphorylated JNK MAP kinase in growth-
arrested, TNF-α exposed (20 min) cells following miR-708 transfection 
(Figure 6A). Further, although total JNK MAP kinase expression remained 
unaltered in these cells (Figure 6B), there was a significant reduction in JNK 
mRNA expression (Figure 6C). We next examined whether reduced JNK 
phosphorylation might be a consequence of increased expression of a 
phosphatase. Expression of a MAP kinase phosphatase, MKP-1, was measured 
by Western blot in miR-708-transfected cells following rh-TNF-α exposure. MKP-
1 expression was significantly higher in cells transfected with miR-708 mimic 
compared to cells transfected with the scrambled sequence mimic (Figure 6D). 
These results suggest that decreased JNK MAP kinase phosphorylation caused 
by increased expression of MKP-1 may be involved in miR-708 regulation 
of CD38 expression in HASM cells. 
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Figure 5. Effect of miR-708 transfection on ERK and p38 MAP kinase 
activation and expression in NA-HASM cells. Western blot analysis of cell 
lysates following transfection with 50 nM miR-708 mimic (mimic) or scrambled 
mimic (scr) and treatment with rh-TNF-α for 20 min (for total and phosphorylated 
levels) or 24 h (for total expression levels) were performed with antibodies 
against phosphorylated and total ERK (A and B) as well as p38 (C and D), 
respectively. Note no significant change in expression of total or phosphorylated 
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ERK (n = 5–6 donors) and p38 (n = 3–5 donors) following miR-708 mimic 
transfection. Each Western blot is a representative blot from a single donor. 
Values are means ± SEM for results shown. C-vehicle-treated cells (0.1%BSA); 
T- rh-TNF-α (10 ng/ml) treated cells. 
 
Figure 6. Effect of miR-708 transfection on JNK MAP kinase signaling in 
NA-HASM cells. A and B: Western blot analysis of cell lysates following 
transfection with 50 nM miR-708 mimic (mimic) or scrambled sequence mimic 
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(scr) was performed as described in Figure 5 to detect JNK MAP kinase after rh-
TNF-α treatment for 20 min (total and phosphorylated levels) (n = 4 donors) as 
well as total JNK expression after rh-TNF-α treatment for 24 h (n = 3 donors). 
Note significant down-regulation of JNK MAP kinase phosphorylation but no 
change in total JNK protein expression in mimic-transfected cells compared to 
cells transfected with scr. C: Total RNA extracted from cells transfected with 
mimic or scr and treated with rh-TNF-α (24 h) was analyzed for JNK mRNA 
expression by q-PCR (n = 3 donors). Note significant down-regulation of JNK 
expression by mimic. D: MKP-1 expression in cells transfected with mimic or scr 
and treated with rh-TNF-α for 24 h was examined by Western blot analysis (n = 5 
donors). Note significant up-regulation of MKP-1 expression in mimic-transfected 
cells compared to scr. Each Western blot is a representative blot from a single 
donor. Values are means + SEM for results shown. C-vehicle-treated cells (0.1% 
BSA); T-TNF-α (10 ng/ml) treated cells. 
 
In a prior study, we reported that regulation of CD38 expression in HASM cells 
involves activation of PI3 kinases(179). Furthermore, PI3 kinase signaling is 
regulated by other miRNAs, including miR-708 (293). Therefore, we measured 
levels of phosphorylated AKT, a molecule in the PI3 kinase signaling cascade, as 
well as levels of PTEN, a phosphatase that terminates PI3 kinase signaling. In 
cells transfected with miR-708 mimic, the level of phosphorylated AKT was 
significantly lower relative to cells transfected with the scrambled sequence 
mimic (Figure 7A). Further, a significant reduction was also noted in the 
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expression of AKT2 (Figure 7B), an isoform of AKT that has a 3’UTR binding site 
for miR-708 (293). In consistence with an overall attenuation of PI3 kinase 
signaling in miR-708-mimic-transfected cells, there was a significant increase in 
PTEN expression compared to expression in cells transfected with the scrambled 
sequence mimic (Figure 7C). A similar increase in PTEN expression was 
observed in AS-HASM cells following miR-708 mimic transfection compared to 
cells transfected with the scrambled sequence mimic (Figure 7D). 
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Figure 7. Effect of miR-708 transfection on PTEN/AKT signaling. A,B and C: 
NA-HASM cells were transfected with 50 nM miR-708 mimic (mimic) or 
scrambled sequence mimic (scr) and treated with rh-TNF-α for 2 h to measure 
total and phosphorylated AKT (n = 3 donors) or 24 h to measure AKT2 (n = 3 
donors) and PTEN expression (n = 8 donors) by Western blot analysis of cell 
lysates. Note significant down-regulation of AKT phosphorylation and AKT2 
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expression and up-regulation of PTEN expression. D: PTEN expression in AS-
HASM cells was higher (not significant) in samples from 3 of 4 donors. Each 
Western blot is a representative blot from a single donor. Values are 
means ± SEM for results shown. C-vehicle-treated cells (0.1% BSA); T-TNF-α 
(10 ng/ml) treated cells. 
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Discussion 
The cell-surface protein CD38 is known to contribute to calcium regulation 
and contractility of ASM (87). In prior investigations, we and others have shown 
that in ASM cells calcium release through ryanodine receptor channels in the 
sarcoplasmic reticulum during agonist stimulation involves cyclic ADP-ribose 
(cADPR) (87, 95, 187). This involves the enzymatic activity of CD38, i.e., ADP-
ribosyl cyclase, which converts β-NAD to cADPR (205, 350). Furthermore, 
exposure of ASM cells to inflammatory cytokines results in significantly 
augmented CD38 expression and cADPR-mediated intracellular calcium 
release (87). These observations strongly implicate the CD38/cADPR pathway of 
calcium signaling in ASM hyperresponsiveness, a hallmark of 
asthma. CD38 deficient mice are also hyporesponsive to inhaled methacholine 
following sensitization and challenge with allergen (120) as well as following 
challenge with inhaled inflammatory cytokines (133, 134). These mice develop a 
robust airway inflammatory response following allergen or cytokine challenge, 
although ASM obtained from these mice exhibit significantly attenuated 
contractile responses to relevant airway spasmogens (133). Furthermore, ASM 
cells obtained from CD38 deficient mice show attenuated intracellular calcium 
responses to spasmogens (89). Together, these results indicate a significant role 
for CD38 in calcium signaling and contractility of ASM and AHR. Therefore, 
delineating the mechanisms that regulate its expression can lead to better 
understanding of changes in ASM function in diseases such as asthma. 
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MiRNAs are known to play critical roles in the regulation of gene expression and 
in disease pathogenesis (30). Recent studies have identified several miRNAs 
whose expression in ASM cells is down-regulated by inflammatory cytokines (66, 
177, 197). There is also evidence for miRNA regulation of ASM contractility (66) 
and relaxation (347) as well as ASM phenotype (162, 197). Increased ASM mass 
due to growth factor-driven ASM cell hypertrophy and hyperplasia is also a 
feature of diseases such as asthma (3, 62, 161, 230) and COPD (366). Recent 
reports have identified the specific role of miR-221 and miR-10a in the regulation 
of ASM proliferation (162, 272). It is interesting to note that miR-10a targets two 
key signaling molecules involved in cell proliferation, i.e., PI3 kinase and ERK 
MAP kinase. MiR-10a suppresses the expression of the catalytic subunit of PI3 
kinase, leading to decreased AKT phosphorylation. 
In this study, we identified miR-708 as a regulator of CD38 in HASM cells. 
We further characterized miR-708 in HASM on the basis that its expression in 
HASM cells is regulated by the inflammatory cytokine rh-TNF-α, which is 
elevated during allergic asthma (59, 146), as well as its differential expression in 
cells from asthmatics versus non-asthmatics, and therefore its potential to 
regulate the expression of genes involved in signaling mechanisms regulating 
inflammation. We report that miR-708 down-regulates CD38 expression through 
mechanisms that involve direct binding to the 3’UTR as well as indirectly by 
regulating JNK MAP kinase and PI3 kinase signaling in HASM cells.  
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Among the numerous potential CD38 3’UTR binding targets that we have 
identified, miR-708 and miR-140-3p (177) appear to play major roles in the 
regulation of CD38 expression in HASM cells. We also observed that transfection 
of cells with both miR-140-3p and miR-708 has no additive or synergistic effects 
on CD38 enzymatic activity, suggesting that either miRNA is capable of 
independently regulating CD38 expression in HASM cells. 
In the current study, we have shown that over-expression of miR-708 
through transfection causes increased PTEN expression and an associated 
decrease in AKT phosphorylation. PTEN expression in certain cancers is 
regulated by miRNAs. A recent study reported that miR-221 and miR-222 
inhibit PTEN expression by binding to the 3’UTR, while knockdown of these 
miRNAs causes induction of PTEN expression (70). PTEN expression in human 
hepatocellular cancer cells is also under the regulation of miR-21 (79). 
Knockdown of miR-21 causes increased PTEN expression in these cells. 
Regulation of PTEN expression in these cancer cell lines by miRNAs has a direct 
effect on tumor cell proliferation, migration and invasion. These studies suggest 
that miRNA regulation of PI3 kinase signaling in ASM cells by altering the 
expression of PTEN would have a profound impact on cell proliferation. In this 
context, a previous study demonstrated that in ASM cells obtained from 
asthmatics, the PI3 kinase/AKT pathway has a major contribution to cell 
proliferation (52). However, in ASM cells obtained from non-asthmatics, cell 
proliferation appears to be regulated by ERK MAP kinase signaling (52). In the 
current study, we found that miR-708 also regulates the phosphorylation of JNK 
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MAP kinase in NA-HASM cells. This effect appears to be a consequence of 
increased expression of MKP-1, a MAP kinase phosphatase. Why this enhanced 
MKP-1 expression is not accompanied by decreased phosphorylation of p38 and 
ERK MAP kinases is not clear. However, it is very likely that the expression of 
some of the upstream kinases involved in the p38 and ERK MAP kinase 
pathways may be increased, compensating for the increased MKP-1 expression. 
It is worth noting that loss of PTEN in certain cancer cells results in increased 
JNK activation independent of AKT and implicating JNK as a component of the 
PTEN/PI3 kinase signaling cascade (343). Thus, it is likely that the decreased 
JNK MAP kinase phosphorylation observed in this study may stem from 
increased PTEN expression. Decreased JNK activation in ASM cells has been 
shown to have an effect on CD38 expression through transcription factors NF-κB 
and AP-1 (322). Our study also shows that ASM cells obtained from asthmatics 
have increased constitutive as well as rh-TNF-α-induced expression of miR-708 
compared to expression in cells from non-asthmatics. The functional effect of 
increased miR-708 expression in these cells remains to be determined. In a prior 
study, we reported a differential induction of CD38 expression in response to rh-
TNF-α treatment in ASM cells from asthmatics (178)  although an enhanced half-
life of CD38 transcript appears not to be an underlying mechanism for this 
differential induction. 
In summary, this study provides evidence for miR-708 regulation 
of CD38 expression in human ASM cells. This regulation stems from direct 
3’UTR binding to the transcript as well as through regulation of signaling 
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involving PI3 kinase and JNK MAP kinase pathways. The inhibition of PI3 kinase 
signaling by miR-708 involves induction of PTEN expression which is likely to 
have a significant impact on ASM cell proliferation and AHR, the latter through 
inhibition of expression of CD38 and potentially other pro-inflammatory genes. 
Our findings suggest the possibility that miR-708 can be used as a potential 
therapeutic strategy to inhibit ASM cell proliferation and contractility. 
Summary figure: 
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Background  
Human airway smooth muscle cells are a source of cytokines and chemokines. 
The expression of chemokine genes is regulated by transcription factors NF-κB 
and AP-1 and involves activation of the MAP kinases and PI3 kinases. In a 
recent study, we reported that miR-708 transfection of HASM cells results in 
significant augmentation of expression of DUSP-1, a MAP kinase phosphatase 
and PTEN, a phosphatase that dephosphorylates Akt to inhibit the PI3 kinase 
signaling. Both these signaling pathways are critical for the expression of several 
pro-inflammatory genes and for regulating cell proliferation. In this study, we 
investigated the regulation of inflammatory gene expression, chemokine release 
and cell proliferation in HASM cells following transfection with miR-708. Gene 
expression results revealed significant downregulation of expression of several 
chemokine genes as well as some genes associated with the asthmatic 
phenotype and functional and pathway analysis showed changes in the 
expression of many of the IL-17 proinflammatory pathway as well as genes 
involved in cell cycle regulation. Validation of the microarray results using q-PCR 
revealed significant downregulation of expression of CCL11, CXCL10, CCL2 and 
CXCL8 as well as asthma related genes such as CD44, ADAM33 and 
RARRESS2. Of the chemokines that were assayed, only CCL11 and CXCL12 
release was inhibited by miR-708 transfection. Serum-induced HASM cell 
proliferation was inhibited by miR-708 transfection. These results indicate a 
profound anti-inflammatory effect of miR-708 in HASM cells with potential to 
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inhibit recruitment of inflammatory cells into the airways and inhibition of cell 
proliferation.    
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Introduction 
Several recent reports have provided evidence that airway smooth muscle 
(ASM) has strong proinflammatory and immunomodulatory functions (80, 85, 
148, 324). These properties of ASM are mediated through its synthetic function 
as well as through expression of a variety of cell-surface molecules, integrins 
(129, 136, 319), and Toll-like receptors (101, 226). During acute airway 
inflammation, mediators and cytokines released from structural and inflammatory 
cells alter ASM contractile function (51, 73, 271, 359). However, during persistent 
airway inflammation, cytokines and chemokines produced by inflammatory cells 
and ASM can cause ASM proliferation, leading to structural changes in the 
airways, often referred to as airway remodeling (142, 185).   During chronic 
airway inflammation, the immunomodulatory role of ASM may be more significant 
in establishing structural changes within the airways than its contractile function. 
In this context, recent reports show that ASM is capable of releasing cytokines 
such as IL-5 (173, 203), IL-6 (11, 236), IL-33 (277), TSLP (368), GM-CSF (298) 
and VEGF (190); chemokines such as RANTES (173), Fractalkine (103), CCL11 
(127), CXCL10 (5, 48, 121), CXCL8(171); adhesion molecules such as ICAM-
1(15, 266), VCAM-1(202, 266), CD44 (201) and LFA-1(131); and growth factors 
such as IGF-1 (255, 281) and stem cell factor (155). Cytokines released by 
immune cells recruited into the lungs during allergic inflammation may also 
stimulate ASM cells to alter the expression of proinflammatory genes in an 
autocrine or paracrine manner. There is also evidence for hypersecretion of 
chemokines both constitutively and in response to cytokines in ASM cells 
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obtained from asthmatics than in cells from non-asthmatics (142, 306). There is 
also increased chemotaxis of mast cells toward ASM cells from asthmatics both 
in vivo and in vitro (9, 48, 261, 312). Other studies have examined the 
transcriptional regulation of expression of chemokine genes in human ASM cells 
(12, 171). While such transcriptional regulation of expression of chemokines is 
better understood, the post-transcriptional regulation is an emerging area of 
investigation. In this context, recent studies provide evidence for specific 
microRNAs in the regulation of ASM proliferation (162, 272), ASM phenotype 
(197) and airway inflammation (231, 328). 
MicroRNAs (miRNAs) are small non-coding ~22nt RNAs that regulate 
gene expression by binding to the 3’-Untranslated Region (3’UTR) of target 
mRNAs to cause mRNA degradation and/or translational repression (29). Since 
binding of miRNAs to target sequences is dependent on its ‘seed’ sequence, a 
single miRNA can potentially regulate a large number of genes. However, 
specific miRNAs are known to regulate cellular functions such as differentiation, 
proliferation, and apoptosis and dysregulation of miRNA expression is known in 
controlling inflammation (29, 137, 138). In a recent report we identified miR-708 
in the post-transcriptional regulation of expression of a cell-surface protein CD38 
through two major signaling pathways (91). Transfection of human ASM cells 
with miR-708 causes the induction of phosphatase and tensin homolog (PTEN), 
which regulates PI3K/AKT signaling by decreasing Akt phosphorylation and is 
involved in NF-κB-regulated genes. MiR-708 also induces DUSP-1, a dual 
specificity phosphatase leading to JNK MAPK dephosphorylation (91). The net 
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effect of PTEN and DUSP-1 induction in ASM cells should lead to modulation of 
two key signaling pathways involved in inflammation and cell proliferation. There 
is evidence that the expression of several chemokine genes in human ASM cells, 
the release of chemokines and cell proliferation are also regulated by these same 
signaling pathways (52, 94, 217, 279, 317). Therefore, in the present study, we 
evaluated differentially expressed genes in human ASM cells following miR-708 
transfection and stimulation with the inflammatory cytokine TNF-α, with particular 
emphasis on the expression of cytokine/chemokine genes, other pro-
inflammatory genes, and those involved in the asthmatic phenotype compared to 
scrambled sequence of mimic transfected cells. From the microarray results of 
differentially expressed genes following miR-708 transfection, we confirmed the 
expression levels of cytokine/chemokine genes, other pro-inflammatory genes, 
and those involved in the asthmatic phenotype using q-PCR. Since many of 
these chemokines are involved in the recruitment of inflammatory cells such as 
eosinophils, basophils, mast cells and T lymphocytes into the airways during 
allergic airway disease, we also measured their release from cells stimulated with 
the inflammatory cytokine TNF-α and following transfection with miR-708.   
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Materials & methods 
Reagents 
Reagents used in the current study: DMEM from GIBCO-BRL (Grand Island, 
NY); rh-TNF-α from R&D Systems (Minneapolis, MN); TRIzol, SuperScript III 
reverse transcriptase, Opti-MEM® reduced serum medium and Lipofectamine® 
RNAiMax transfection reagent from Invitrogen Life Technologies (Carlsbad, CA); 
Brilliant lll Ultra-Fast SYBR Green q-PCR Master Mix from Agilent Technologies 
Inc (Santa Clara CA); control oligo (scrambled sequence mimic) and miR-708 
mimic (mature miR-708 sequence: 5’-AAGGAGCUUACAAUCUAGCUGGG-3’) 
from Dharmacon (Lafayette, CO); CyQUANT® NF Cell Proliferation Assay Kit 
from Thermo Fisher Scientific brand Life technologies ( Eugene, Oregon 97402); 
Tris-base, glucose, HEPES and other chemicals from Sigma Chemical Co. (St. 
Louis, MO). 
Microarray sample preparation 
ASM cells, derived from three de-identified healthy donors, used between 2-5th 
passages, were seeded at 1.5 X 105 cells/well and transfected with mimic or 
scrambled sequence mimic of miR-708 at 50 nM concentration (91). We used the 
same concentration which was previously determined to be optimal to inhibit the 
expression of CD38 (91). Cells that were growth arrested (24 h) after 
transfection, were induced with pro-inflammatory cytokines TNF-α at 10 ng/ml 
(24 h).  Total RNA was harvested using PureLink RNA isolation kit according to 
the manufacturer’s instructions. Purity of the RNA was determined with a 
Nanometer 2000C for the ratios 260/280 and 260/230. For each condition (mimic 
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or scrambled oligo treatment) 1000 ng of total RNA was subjected to microarray 
analysis. Genome-wide changes in gene expression in transfected cells were 
generated using Illumina human (HT-12) arrays and analyzed using BeadStudio 
version 3.1.1. 
Data Analysis 
For statistical analysis and clustering, we used the Partek Genomics Suite 
software package (Partek Inc., St. Louis, MO, USA). We performed a paired t-
test with donor ID and mimic/control as the nominal variables. Before comparison 
analysis and clustering, we filtered extremely low and non-variant genes out of 
the datasets. Significance cutoff filters were set at P < 0.05 and an expression 
change of at least 2-fold. For functional and pathway analyses we used Ingenuity 
Pathway Analysis (IPA) software (Qiagen, Redwood City, CA, USA). IPA 
employs a right-tailed Fisher exact test to calculate a P value corresponding to 
the probability that a biologic function not relevant to the input dataset is falsely 
identified as relevant. A Benjamini–Hochberg false discovery rate of 0.05 was 
used to correct such P values. 
 Validation of genes by q-PCR 
As described in the “Microarray sample preparation”, total RNA was 
isolated and cDNA was prepared using reverse transcription kit from Invitrogen 
Life Technologies (Carlsbad, CA). cDNAs were subjected to q-PCR analysis 
using Brilliant SYBR Green Master Mix and Stratagene Mx3000p q-PCR system 
(Foster City, CA). Primer sequences and conditions for the genes tested are 
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provided in Table 1. The β-actin gene was used as a housekeeping gene to 
normalize the expressions of other genes. 
Table 1: Primer sequences for chemokine genes 
Gene primer sequences 
CXCL10 F: 5' - 3' GAACTGTACGCTGTACCTGCA 
  R: 5' - 3' TTGATGGCCTTCGATTCTGGA 
CXCL8 F: 5' - 3' ACTGAGAGTGATTGAGAGTGGAC 
  R: 5' - 3' AACCCTCTGCACCCAGTTTTC 
CCL5 F: 5' - 3' CAGTCGTCTTTGTCACCCGAA 
  R: 5' - 3' TCCCAAGCTAGGACAAGAGCA 
CCL2 F: 5' - 3' AGGTGACTGGGGCATTGAT 
  R: 5' - 3' GCCTCCAGCATGAAAGTCTC 
CXCL12 F: 5' - 3' TGCCAGAGCCAACGTCAAG 
  R: 5' - 3' CAGCCGGGCTACAATCTGAA 
CCL11 F:  5' - 3' CCCCAGAAAGCTGTGATCTTCA 
  R: 5' - 3' GGAGTTGGAGATTTTTGGTCCAGAT 
RARRES2 F: 5' - 3' GAGGGACTGGAAGAAACCCG 
  R: 5' - 3' CATGGCTGGGGATAGAACGG 
ADAM33 F:  5' - 3' GACCTAGAATGGTGTGCCAGA 
  R:  5' - 3' AGCCTGGC TTGTCACAGAAG 
CD44 F:  5' - 3' AGCATCGGATTTGAGACCTG 
  R: 5' - 3' GTCCACATTCTGCAGGTTCC 
β-Actin F:   5' - 3' ACACTGTGCCCATCTACGAGG 
  R:  5' - 3' AGGGGCCGGACTCGTCATACT 
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Chemokine Release assay 
Human ASM cells were transfected with mimic or scrambled sequence 
mimic of miR-708 or were untransfected (control) as described in an earlier 
publication (91).  Cells were then growth arrested and treated with 10ng/ml TNF-
α. Cell culture supernatants were collected at different time points ranging from 
6-48 h. Collected supernatants were aliquoted and immediately stored at -80 o F 
until assayed. Chemokines in the culture supernatants were quantified using 
ELISA kits from R&D system according to the manufacturer’s instructions 
(Minneapolis, MN 55413). 
Proliferation assay 
Human ASM cells derived from healthy donors were transfected with 
mimic or scrambled sequence mimic of miR-708 and seeded at a concentration 
of ~7000 cells/well in 96 well plates. RNAimax was used to facilitate the 
transfection according to the manufacturer’s instruction (Invitrogen Life 
Technologies). Twenty four hours after plating, the cells were growth arrested 
with serum deprived media that was supplemented with insulin and transferrin. 
After 24 h, cells were treated with 10% fetal bovine serum for 48 h and the 
number of cells enumerated using the Cyquant assay kit according to the 
manufacturer’s instructions (20) (Thermo Fisher Scientific brand Life 
technologies).  
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Results 
 Microarray results 
Gene expression results are shown as a heatmap (Figure 1). Visual 
inspection easily identifies differential patterns of expression between samples 
treated with a miR-708 mimic (purple bar) versus a scrambled control (orange 
bar). Principal Component Analysis (PCA) confirmed the mimic as the primary 
differential component (Figure 2). Our analysis found that 821 genes were 
differentially expressed (348 upregulated and 473 downregulated) in HASM cells 
transfected with a miR-708 mimic versus a scrambled control sequence (paired t-
test, P < 0.05). Table 2 summarizes the differentially expressed 
chemokines/cytokines, transcription factors, extracellular matrix components, 
calcium signaling molecules, growth factors and other genes related to airway 
hyperresponsiveness. The complete list of genes is available as Supplemental 
Table 1.  
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Figure 1: Heatmap of mRNA microarray expression data. Purple bar indicates 
samples treated with the miR-708 mimic; orange bar indicates samples treated 
with a scrambled control. Sample rows are arranged in the same donor-order 
(i.e. donor 1 samples are rows 1 and 4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PCA Analysis showing a clear primary separation of samples based 
on miR-708 mimic versus scrambled control. Secondary separation was by donor 
ID.  
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Table 2. Summary of differentially expressed genes 
  Gene ID 
fold 
change Function 
Inflammatory 
mediators       
Chemokines  CXCL10 -2.695 Chemoattracts  mast cell  
  CCL8 -5.38 Chemoattracts monocytes  
  CCL11 -8.968 Chemoattracts Eosinophils  
  CXCL12 -5.254 
Chemoattractant T-lymphocytes & 
monocytes  
  CCL5 -3.52 Chemoattracts Eosinophil  
  CCL2 -3.21 
Chemoattracts  monocytes, fibrocytes and 
basophils  
 CXCL8 -2.03 
Chemoattracts neutrophils, basophils and 
T-cells  
 CXCL16 -2.688 Scavenger receptor on macrophages 
 CXCL5 -2.389 Activates neutrophils  
 CXCL9 -2.375  Chemoattracts activated T-cells 
 CXCL11 -2.151 
Chemoattracts interleukin-activated T-
cells 
 CXCL6 -2.039 Chemoattracts neutrophil, granulocytes 
Cytokines    
  IL18BP -4.028 Inhibits the early TH1 cytokine response 
  IL6 -1.832 
Stimulates the differentiation of B-cells 
and acts as a myokine. 
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TNFSF13
B -4.216 Stimulates B- and T-cell function 
Genes associated with 
ECM        
 VCAM1 
-20.59 Enhances leukocyte-endothelial cell 
adhesion and T cell inflammatory 
functions 
  COL3A1 -9.808 Activates RhoA pathway 
  COL6A1 
-3.185 A major structural component of 
microfibrils 
  CD44 -4.25 
Increases airway hyperresponsiveness 
(122); leads to inflammation (182, 183) by 
interacting with T-cell (201) and mast cell 
(128); increases  ASM cell proliferation (3) 
  THBS1 -4.797 Increases IL-8 production (165)  
  MXRA5 -4.581 Associates with matrix-remodeling protein 
 
ADAMTS-
1 6.158 Increases FEV1 (269) 
 TAPBP -4.38 
Increases antigen processing and 
assembly of MHC class I (17) 
Transcription factors       
  NFκB1       -1.876 Regulates immune response  
  RELA -1.728 Regulates immune response 
Calcium signaling       
  CD38 -2.286 Increases cell adhesion, signal 
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transduction, AHR and calcium signaling. 
  
BDKRB1 
 -1.994 
Increases chronic and acute inflammatory 
responses 
  FKBP10 -2.198 Regulates [Ca2+]i dynamics 
Growth factors and 
related genes       
  IGFBP5 -4.009 Prolongs the half-life of the IGFs 
  PDGFRL -4.258 Increases proliferation 
  EGFL6 -3.886 
Regulates of cell cycle & induces 
proliferation  
Airway 
hyperresponsiveness    
 ACTG2 -17.181 Increases muscle contraction 
 TAGLN -4.691 
Increases calcium interactions and 
contractility 
 MYLK -2.12 Increases Smooth muscle contraction 
 PDE5A -2.50 Inactivates of cGMP (108) 
Genes associated with 
proliferation F2F7 6.8 Blocks proliferation  (82) 
 IL24 11.6 Anti-proliferative (360)  
 COL1A1 -7.474 Increases ASM cell proliferation (151) 
 DUSP6 10.915 Decreases ASM cell proliferation 
 UBE2C 18.96 Increases cell proliferation 
 CDC20 16.459 Increases cell proliferation 
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 ID1 16.089 Increases cell proliferation 
 ANGPTL4 12.633 Increases ASM cell proliferation (309) 
 CDK1 5.387 Increases cell proliferation 
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Functional and Pathway Analysis 
The most significant biologic functions for this differential gene set 
included decreased inflammatory response, cytokine expression and signaling. In 
particular, many components of the IL-17 proinflammatory pathway were 
downregulated. Multiple pathways and biologic functions related to cell cycle 
progression were predicted to be upregulated. 
 
 
 
 
 
 
 
 
Figure 3. Network diagram showing potential regulatory pathways 
connecting miR-708 and down-regulated molecules of interest in human 
ASM cells. Note significant down-regulation of several chemokine genes, CD44, 
and CD38. Genes are colored either by observed expression changes in the 
paired t-test (Green, fold decrease given below gene name) or by predicted 
activation status (Blue = predicted inhibition) based on the assumption of 
increased miR-708 (Red). Potential relationships are indicated by solid (direct 
interaction) or dotted (indirect interaction) lines. Interaction lines are colored 
based on whether the predicted relationship leads to inhibition (Blue), leads to 
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activation (Yellow; inconsistent with observed results), or effect was not able to 
be predicted (Gray). 
 
miR-708 inhibits chemokine mRNA expression and other asthma related 
genes 
Results of gene expression analysis revealed significant downregulation of 
expression of several chemokine genes as well as some genes associated with 
the asthmatic phenotype. Therefore, we used q-PCR analysis to validate the 
microarray results of expression of these genes. Human ASM cells were 
transfected with miR-708 mimic oligonucleotides or the scrambled control and 
then treated with TNF-α. Twenty four hours following the addition of TNF-α, total 
RNA was collected from the cells and subjected to q-PCR analysis. There was 
significant inhibition in the expression of chemokine genes CCL11 (p=<0.0001), 
CXCL10 (p=0.0308), CCL2 (p=0.0422) and CXCL8 (p=0.0156) (Figure 4) as well 
as other ‘asthma related’ genes such as CD44 (p=0.0328), ADAM33 (p=0.0016) 
and RARRESS2 (p=0.0006) (Figure 5). On the other hand, the mRNA 
expression levels for chemokine genes CCL5 (p=0.0549) and CXCL12 following 
transfection with the miR-708 mimic were not significantly different from 
expression in scrambled miR-708 oligonucleotide-transfected cells (Figure 5).    
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Figure 4. Downregulation of chemokine mRNA expression following miR-
708 transfection. Human ASM cells derived from 3-5 donors were transfected 
with mimic or scrambled (Scr) sequence mimic of miR-708 followed by exposure 
to TNF-α (10ng/ml) to measure chemokine mRNA expression. Note the 
significant inhibition in the expression of CCL11, CXCL10, CXCL8 and CCL2 
following miR-708 mimic transfection compared to expression in cells transfected 
with scrambled sequence. Data represent mean±SEM. 
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Figure 5. Down regulation of other ‘asthma related’ genes by miR-708. 
HASM cells obtained from 3-5 donors were transfected with mimic or scrambled 
sequence mimic (control) of miR-708 followed by treatment with TNF-α 
(10ng/ml/). Note significant inhibition of expression of CD44, ADAM33 and 
RARRES2 transcripts in miR-708 mimic-transfected cells compared to 
expression in scrambled sequence transfected cells. Data represent mean±SEM. 
miR-708 transfection and release of chemokines. 
To determine whether changes in the mRNA expression of chemokines 
were reflected in their protein expression, we measured their release in HASM 
cell culture supernatant following miR-708 mimic or scrambled sequence mimic 
transfection and TNF-α induction. As a control, we collected the culture 
supernatant from untransfected but TNF-α treated HASM cells.  Of the 
chemokines that were assayed, only CCL11 release exhibited significant down 
regulation of release in mimic miR-708-transfected cells compared to release 
from cells transfected with the scrambled miR-708 oligonucleotides or from 
control cells at all-time points examined (Figure 6). CXCL12 release on the other 
hand exhibited significant inhibition following addition of TNF-α at 24 h but not at 
earlier time points (Figure 6). 
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Figure 6. Chemokine release from HASM cells following miR-708 
transfection. HASM cells from 3-6 donors were transfected with mimic or 
scrambled sequence mimic of miR-708 and treated with TNF-α (10ng/ml) 
following growth arrest of cells. Twenty hours later cell culture supernatants were 
collected for the measurement of chemokines. Note the release of CCL11 was 
significantly inhibited at every time point following miR-708 transfection when 
compared to scrambled sequence mimic transfection. The release of CXCL12 
was significantly inhibited only at 24 h, relative to control. Data represent 
mean±SEM.  
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miR-708 inhibits proliferation of HASM cells  
Functional and pathway analysis of differentially expressed genes following miR-
708 transfection revealed changes in the expression of several genes involved in 
cell cycle progression/regulation. Therefore, we examined the effect of miR-
708mimic transfection on serum-induced HASM cell proliferation. HASM cells 
were transfected with mimic or scrambled sequence of mimic miR-708 
oligonucleotides and exposed to 10% serum for 48 h. Cell proliferation measured 
using the Cyquant assay showed significant inhibition of proliferation in cells 
transfected with the mimic miR-708 as compared to cells transfected with the 
scrambled miR-708 oligonucleotides (Figure 7).  
 
Figure 7. miR-708 decreased the proliferation of HASM cells. HASM cells 
derived from 4-6 donors were transfected with mimic or scrambled sequence 
mimic of miR-708 followed by treatment with 10% bovine fetal serum for 48 h. 
Proliferation of cells was measured using Cyquant proliferation assay kit. Note 
significant inhibition of proliferation of cells transfected with mimic of miR-708 
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relative to cells that were transfected with scrambled sequence mimic of miR-
708. Data represent mean±SEM. 
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Discussion   
Using a transcriptomics-based approach, we investigated differentially 
expressed genes in human ASM cells treated with TNF-α following miR-708 
transfection compared to expression in cells transfected with the scrambled 
mimic oligonucleotides. This analysis revealed significant changes in the 
expression of several genes, including those for chemokines / cytokines, 
extracellular matrix proteins, transcription factors, calcium signaling molecules, 
growth factors, and genes associated with airway hyperresponsiveness. Several 
genes involved in cell cycle regulation were up-regulated, although E2F7, 
DUSP6 and IL-24, genes that block cell proliferation, were significantly up-
regulated. The net functional effect of these changes in gene expression was 
reflected in inhibition of serum-induced cell proliferation. There was down-
regulation of expression of JNK MAP kinase which is involved in serum-induced 
ASM cell proliferation (64). The changes in the expression of chemokine genes 
revealed in this approach were confirmed by q-PCR. In addition, miR-708 also 
produced down-regulation of expression of several ‘asthma-related’ genes such 
as CD44 (182, 201), ADAM33 (154, 337) and RARRES2 (37, 145, 228). Prior 
reports have shown that CD44 is involved in mast cell-ASM cell adherence 
through Type I collagen and this adherence is greater during airway inflammation 
as well as in ASM cells derived from asthmatics (128).   
In the present study, we examined the post-transcriptional regulation of 
expression of several inflammatory genes in human ASM cells by miR-708. In a 
recent study in human ASM cells stimulated with the inflammatory cytokine TNF-
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α, we showed that transfection with miR-708 caused a significant augmentation 
of PTEN and DUSP-1 expression, with concomitant decreased activation of Akt 
and JNK MAP kinase respectively (91). The PI3 kinase/Akt and MAP kinase 
signaling mechanisms are clearly involved in airway inflammation by activating 
transcription factors such as NF-κB and AP-1 (106, 211, 283, 357). Recent 
reports have shown that this signaling is involved in the hyperproliferative 
phenotype of ASM cells from asthmatics (52). The promoter regions of several 
chemokine genes contain binding sites for NF-κB and AP-1 as well as for other 
transcription factors (10, 126, 286). Furthermore, TNF-α is capable of inducing 
the expression and release of these chemokines from human ASM cells as well 
(9, 12, 14, 32, 127). Although the mechanisms by which miR-708 decreased the 
expression of the chemokine genes that we examined are not addressed in this 
study, miRNA target prediction algorithms showed 3’UTR targets for miR-708 for 
CXCL12 and CCL5 but not for the other chemokines examined. It is very likely 
that the inhibition of expression of chemokine genes following miR-708 
transfection resulted from indirect mechanisms of decreased activation of 
transcription factors and MAP kinases involved in their regulation. 
We examined the expression and release of several chemokines from 
human ASM cells stimulated with TNF-α in this study. There was significant 
inhibition of expression of chemokines involved in the recruitment of eosinophils, 
mast cells, T lymphocytes and fibrocytes following miR-708 transfection of 
human ASM cells. However, chemokine release studies revealed that there was 
inhibition of release of CCL11 and CXCL12. It is interesting to note that our 
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microarray results showed a high level of down-regulation of CXCL12 
expression, while the q-PCR results did not show any change in CXCL12 
transcript levels following miRNA transfection. It is very likely that miR-708 may 
regulate transcription and release of some chemokines while it may have a 
dominant effect on release for others. It is also known that production of specific 
chemokines in ASM cells may involve unique signaling pathways and stimuli, as 
has been shown for CXCL10 release (9).  In this study, the authors demonstrated 
that in human ASM cells exposed to TNF-α or IL-1β, CXCL10 production 
required JNK MAP kinase activation, while its release was induced by p38 MAP 
kinase activation. The results of the microarray analysis of differentially 
expressed genes and q-PCR results confirmed selective down-regulation of JNK 
MAP kinase expression by miR-708, with decreased JNK MAP kinase 
phosphorylation. Recent investigations have shown that stimulation of ASM cells 
with a mixture of cytokines causes significantly higher amounts of chemokine 
release than following exposure to individual cytokines (172, 317). It should be 
emphasized that in our study chemokine release was measured from cells 
following miRNA transfection and growth-arrest, before stimulation with TNF-α. It 
will be interesting to examine release of chemokines in response to a mixture of 
cytokines following miR-708 transfection. 
There was also attenuation of serum-induced proliferative response of 
ASM cells following miR-708 transfection. Although the molecular mechanisms 
underlying this attenuation are not addressed in this study, it is likely that it 
stemmed from inhibition of JNK MAPK and PI3 kinase/Akt activation by miR-708 
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that we reported in our earlier study (91) and confirmed in this study for JNK 
MAPK. 
In conclusion, this study demonstrates a profound anti-inflammatory effect 
of miR-708 in human ASM cells stimulated with the inflammatory cytokine TNF-α, 
with significant down-regulation of expression and release of several important 
chemokines involved in the recruitment of inflammatory cells into the airways 
during allergic airway inflammation. Serum-induced ASM cell proliferation is also 
attenuated by miR-708 transfection, which should have an impact on airway wall 
remodeling in asthma. 
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CHAPTER v 
Conclusions and future directions 
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General Conclusions and Future Directions  
My goal was to determine whether microRNAs play a role in regulating the 
expression of CD38 and altering the phenotype of human airway smooth muscle 
(HASM) cells.  Using bio informatics/ algorithms such as TargetScan, MIRDB, 
DIANA and PITA, the following microRNAs predicted to have target sites at the 
3’-UTR of CD38 mRNA were selected based on high context score: miR-140-3p, 
miR-20a, miR-20b, miR-708, miR-1272, miR-208a, miR-548 and miR-1298. The 
pattern of expression of these microRNAs in HASM cells in the presence of the 
pro-inflammatory cytokine TNF-α (or vehicle as control) was determined by q-
PCR. MicroRNAs miR-140-3p and miR-708 were differentially expressed in 
HASM cells in the presence of TNF-α, showing a CT value of 35 or lower in the 
q-PCR analysis and were selected for further studies. My work is primarily based 
on the regulation of the expression of CD38 and other asthma related genes by 
miR-708 in HASM cells. 
MicroRNAs are powerful gene modulators (29). Aberrantly expressed 
microRNAs cause disturbances in cellular processes, which lead to diseases. 
Several microRNAs have been implicated in the pathophysiology of asthma, 
such as miR-133a in bronchial hyperresponsiveness (65) as well as miR-10a 
(162), miR-221 (272) and miR-25 (197) in airway smooth muscle hyperplasia. 
Since miR-708 was predicted to have a target site at the 3’UTR of CD38, a 
known player in AHR, we sought to determine whether miR-708 might play a 
regulatory role in the expression of CD38. Accordingly, I first transiently 
transfected the mimic of miR-708 or a control microRNA (scrambled sequence 
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mimic) at different concentrations into HASM cells and measured the expression 
of CD38 at mRNA and protein levels, using q-PCR and reverse cyclase assays, 
respectively. I found that miR-708 inhibits the expression of CD38 at 50 nM and 
100nM but not at 10nM. This concentration (10nM) may not be the optimum 
(threshold) concentration for miR-708 to initiate its inhibitory effect on the 
expression of CD38.  
Conclusion 1: 
miR-708 regulates the expression of CD38 at mRNA and protein level  
MicroRNAs exert their inhibitory effect mostly by directly binding to the 
3’UTR of their target mRNA (29, 30). Therefore, to determine whether miR-708 
directly binds to the predicted target site at the 3’UTR of CD38 and regulates 
gene expression, NIH-3T3 cells were transiently transfected with luciferase-
reporter-plasmids with CD38-3’UTR constructs and mimic of miR-708 or 
scrambled sequence mimic as a control. Here I used a heterologous cell system 
(NIH-3T3) to perform this assay because HASM cells are primary cells and are 
technically challenging to transfect with larger plasmids. I found that the relative 
luciferase activity in cell lysates obtained from cells transfected with the mimic of 
miR-708 was lower compared to lysates of cells transfected with scrambled 
sequence mimic or the luciferase-reporter–plasmid alone. The specificity of 
target binding by miR-708 was confirmed by mutating four bases in the target 
sequence which reversed the inhibitory effect of miR-708 on luciferase gene 
expression.  
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Conclusion 2: 
miR-708 has specific functional and putative target sites at the 3’UTR 
of CD38. 
MicroRNAs regulate the expression of genes post-transcriptionally by 
binding to their target site at the 3’UTR of mRNA and degrading it or repressing 
translation, depending on the degree of sequence complementarity (29, 30). We 
performed mRNA stability assays to determine whether miR-708 inhibits the 
expression of CD38 by degrading the transcript. After transfection with mimic of 
miR-708 and growth arrest, HASM cells were treated with TNF-α for 12 h to 
induce CD38 expression. Actinomycin D was used to arrest further transcription 
and total RNA was collected at different time points to analyze the expression 
level of CD38 relative to 0 time point using non-linear regression analysis.  I 
found that binding of miR-708 to its target site did not result in degradation of 
CD38 mRNA, therefore miR-708 should have caused translational repression.  
Conclusion 3: 
miR-708 does not regulate the expression of CD38 through 
degradation of CD38 mRNA.  
MicroRNAs can indirectly regulate the expression of a target gene by 
regulating multiple constituents in signaling pathways (168). Since the expression 
of CD38 at mRNA level was significantly inhibited by miR-708, I sought to 
determine whether miR-708 regulates expression of CD38 at the level of 
transcription. Because MAPK and PI3K signaling pathways transcriptionally 
145 
 
regulate the expression of CD38 in the presence of TNF-α, I examined the 
activation and expression level of genes in these pathways. I found that following 
miR-708 transfection, activation of JNK MAPK and Akt in TNF-α-treated HASM 
cells was inhibited and the expression of their phosphatases, MKP-1 and PTEN, 
respectively was elevated.  
Conclusion 4: 
miR-708 transcriptionally regulates the expression of CD38 through 
inactivating JNK MAPK and Akt and increasing the expression of their 
inhibitors MKP-1 and PTEN.  
Since miR-140-3p is also differentially expressed in HASM cells treated 
with TNF-α, I examined whether this microRNA plays a role in regulating the 
expression of CD38. Over-expression of miR-140-3p in cells transfected with the 
mimic of this microRNA inhibited the expression of CD38 in a concentration-
dependent manner at mRNA and protein level. Luciferase reporter assays as 
described earlier with miR-708 confirmed direct and specific (by site-directed 
mutagenesis) interaction of miR-140-3p with the 3’-UTR target binding site of 
CD38. Further, I observed that as in the case of miR-708, miR-140-3p 
transfection did not alter CD38 mRNA stability. Since transcript degradation was 
not the cause for decreased levels of CD38 mRNA, I sought to determine 
whether miR-140-3p exerts its regulatory effect on CD38 expression at a 
transcriptional level.   
Western blot analysis to detect the level of expression and activation 
status of signaling molecules in the MAPK and PI3K pathway as well as of the 
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transcription factors NF-κB and AP-1 revealed that over expression of miR-140-
3p decreases the activation of p38 MAPK and NF-κB (figure 1).  
Conclusion 5:  
MiR-140-3p regulates the expression of CD38 post-transcriptionally 
by binding to its putative target site and transcriptionally by inactivating 
p38 MAPK and transcription factor NF-κB.  
MicroRNAs simultaneously regulate several genes that accomplish a 
cellular process or a tissue function.  In order to determine whether miR-708 
transfection alters expression of other asthma related genes, I performed a 
microarray analysis of total RNA isolated from HASM cells that were transfected 
with mimic of miR-708 or scrambled sequence mimic and treated with TNF-α. 
Interestingly, I found that several inflammation-associated genes such as 
chemokines, cytokines, genes associated with extracellular matrix components 
and genes related to TNF-α and NF-κB were down-regulated. Decreased 
expression of some of these inflammatory genes such as CCL11, CXCL10, 
CXCL8, CCL2, RARRES2 (retinoic acid receptor responder 2) and extra cellular 
matrix associated genes such as ADAM33 (a disintergrin and metalloprotease 
33) and CD44 was validated by q-PCR. Chemokines secreted by HASM cells 
play an important role during inflammation by attracting/recruiting inflammatory 
cells to the airways. Chemokines CCL11, CXCL10, CXCL8, CCL2 and 
RARRES2 have been shown by other investigators to recruit eosinophils, mast 
cells, neutrophils, monocytes, dendritic cells and macrophages, respectively. We 
measured the release of CCL11, CCL5, CXCL10, CXCL8 and CXCL12 in the 
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culture supernatant of HASM cells transfected with mimic of miR-708 or 
scrambled sequence mimic at different time points ranging from 6-48h. We found 
that the release of only CCL11 was inhibited by miR-708 transfection with a 
coordinated decrease at the mRNA level. Although the expression of other 
chemokines was inhibited at the mRNA level, there was no corresponding 
decrease at the protein level.  This suggests that these chemokines might be 
stored in vesicles or in pre-formed granules as seen in other  cell types such as 
eosinophils, endothelial cells, mast cells, etc., and when TNF-α is added to the 
cell culture they are readily released. Expression and release of these 
chemokines from HASM cells is known to be controlled by various signaling 
pathways depending on the type of trigger. IL-17A-induced expression of CCL11 
involves the MAPK pathway (279), while TSLP-induced expression of CC/CXC 
chemokines involves MAPK and STAT3 pathways (301). Likewise, IL-β-induced 
release of CCL11, CCL2 and CCL7 involves activation of the MAPK pathway as 
well as the transcription factor NF-κB (357) and IL-13-induced release of CCL11 
involves MAPK and STAT-6 signaling pathways (270). Therefore it is possible 
that signaling pathways that are not regulated by miR-708 may be involved in the 
release of the chemokines CCL5, CXCL10, CXCL8 and CXCL12 and when the 
cells are exposed to TNF-α, irrespective of whether miR-708 is present or not, 
HASM cells readily released these chemokines. On the other hand, it is also 
possible that mRNAs of these chemokines that were transcribed prior to miR-708 
transfection/over-expression undergo protein translation and are released. In this 
case, differences in the release of these chemokines following miR-708 
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transfection may be detected in the culture supernatant at later time points. 
However, taking into consideration that this is a transient transfection system and 
the half-life of microRNAs within cells after transfection in vitro is about 3-5 days, 
we collected supernatants only up to 48h. Studies from other laboratories 
suggest that using a mixture of cytokines (cytomix) containing IFN-γ, IL1-β, and 
TNF-α instead of TNF-α alone may enable detection of differences in the release 
of these other chemokines compared to control (cells transfected with scrambled 
sequence mimic) (9, 91). Establishing stable transfection using viral vectors is 
technically challenging since the procedure entails several passages of cells for 
the selection of successfully transected cells which may lead to loss of smooth 
muscle phenotype in HASM primary cells.  
CD44, a cell surface glycoprotein, is a key receptor for hyaluronan and a 
major component of the extra cellular matrix which plays a role in airway 
remodeling and AHR.  Further, CD44 has been shown to promote the homing of 
activated T-lymphocytes to asthmatic airways (201). Studies have shown that 
allergen-challenged CD44-deficient mice exhibit markedly attenuated AHR 
compared to wild type (WT) mice and that administration of antibodies against 
CD44 to allergen-challenged WT mice results in reduced AHR (122).  Thus, 
inhibition of the expression of CD44 by miR-708 is likely to have a beneficial 
effect on asthma-related symptoms. Likewise, down-regulation of ADAM33 and 
RARRES2 gene expression by miR-708 is also likely to be beneficial in asthma 
since both have been implicated in asthma. ADAM33 is an asthma susceptibility 
gene strongly associated with bronchial hyperresponsiveness with a role in 
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airway remodeling by promoting fibroblast hyperplasia (212, 225, 246, 337) and 
RARRES2, is a chemoattractant for dendritic cells and macrophages (166, 355, 
356).   
Microarray analysis of miR-708-transfected cells also revealed inhibition of 
expression of various other genes that could impact inflammation such as (i)  
those associated with extracellular matrix, i.e.,  collagen types 1,3 and 6, VCAM, 
THBS1, MXRA5; (ii) TNF-α related genes, i.e., TNFRSF11B and TNFSF13B; (iii) 
genes related to smooth muscle contraction, i.e., TAGLN, MYLK, ACTG2; (iv) 
transcription factors, i.e., NF-κB1 and RELA;  (v) growth factor related genes 
such as IGFBP5, PDGFRL, EGFL6. In addition, up regulation of important genes 
such as PPIL5 that suppress the activation of NF-κB, DUSP6 that inactivates 
MAPKs, BMP2 that up-regulates PTEN and IL-24 that has anti-inflammatory and 
anti-proliferative properties was also noted. 
Conclusion 6: 
miR-708 inhibits the expression of several inflammatory genes 
including chemokines CCL11, CXCL10, CXCL8, CCL2 and RARRES2, 
extracellular matrix components CD44 and ADAM33 as well as the release 
of CCL11 by HASM cells. 
Proliferation of HASM cells causes thickening of the airway wall and 
obstruction of airflow. Several studies have shown that thickening of the airway 
wall due to increased smooth muscle mass increases airway resistance. Further, 
studies have also shown that the MAPK and PI3K signaling pathways regulate 
the proliferation of HASM cells. MicroRNAs such as miR-10a and miR-221 have 
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been shown to play a role in the proliferation of HASM cells. miR-708, a focus of 
the current study, has been implicated in many cancer-related studies and is 
shown to have anti-proliferative as well as pro-proliferative properties, depending 
on the type of cancer. Given the role of MAPK and PI3K signaling pathways in 
regulating the proliferation of HASM cells, participation of miR-708 in down-
regulating these signaling pathways as shown in the current study may have an 
inhibitory effect on proliferation of HASM cells (figure 1). In the microarray data, 
we found that expression of an almost equal number of pro-proliferative and anti-
proliferative genes were altered in HASM cells transfected with mimic of miR-708 
and treated with TNF-α. To further, explore this, we performed proliferation 
assays using the CYQUANT cell proliferation assay kit with HASM cells following 
transfection with mimic of miR-708 or scrambled sequence mimic in the presence 
of TNF-α or 10% fetal bovine serum. miR-708 was found to inhibit the 
proliferation of NA-HASM cells by about 37% in the presence of fetal bovine 
serum.  
Conclusion 7:  
miR-708 has an anti-proliferative function in HASM cells. 
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Figure 1. Proposed model for the microRNA regulation of CD38 and other 
asthma related genes, based on the findings of the present investigation. 
 
 
 
Figure 1: Model depicting regulation of chemokine gene expression 
and proliferation of human airway smooth muscle cells: 
Exposoure of human airway smooth muscle cells to the inflammatory cytokine 
TNF-α causes activation of the MAP kinases and PI3 kinase signaling pathways. 
These results in augmented expression of the cell-surface protein CD38 through 
transcription factors NF-κB and AP-1 to cause increased calcium signaling, 
contractility and airway hyperresponsiveness (AHR). TNF-α also causes 
increased ASM cell proliferation through MAP kinase and PI3 kinase/Akt 
signaling pathways. The expression and secretion of several chemokines from 
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ASM cells is significantly increased on exposure to TNF-α. MiR-708, by 
increasing the expression of a dual specificity phosphatase (DUSP-1) decreases 
JNK MAP kinase phosphorylation, resulting in decreased expression of CD38 
and several chemokine genes. By inducing the expression of PTEN, a 
phosphatase that inactivates Akt, miR-708 can inhibit cell proliferation as well as 
CD38 expression. MiR-140-3p, on the other hand, decreases activation of p38 
MAP kinase and NF-κB resulting in decreased CD38 expression. MiR-140-3p 
effects on inhibition of chemokine gene expression and secretion may also be 
exerted through decreased activation of p38 MAP kinase and NF-κB.  
Future Direction 1:  
Test efficacy of miR-708 in down-regulating allergen-induced airway 
inflammation and AHR in mouse models: Cholesterol-incorporated, nucleotide-
locked miR-708 will be administered intranasally or intravenously to asthmatic 
mice and pulmonary function assays (plethysmography) as well as airway 
inflammation based on total and differential cell counts in BAL fluid will be 
determined. To compare miR-708 versus an inhibitor of CD38 in controlling AHR 
and inflammation, the CD38 inhibitor (modified NAD) will be delivered 
intranasally to allergen-challenged WT mice and airway inflammation will be 
assessed.  I anticipate that allergen-challenged mice administered with miR-708 
will exhibit lower AHR than mice that received CD38 inhibitors though species 
differences and species specific functions may interfere with the results.  
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Future Direction 2:  
Previous studies from our laboratory have shown that asthmatic CD38-/- chimeric 
mice that were transplanted with WT bone marrow demonstrate partial rescue in 
airway resistance to contractile agonists.  To determine whether CD38 expressed 
by inflammatory cells have a role in controlling airway contractility, an inhibitor of 
CD38 will be administered to these mice and pulmonary function will be 
measured. Here I anticipate that chimeric mice that received the inhibitor will 
exhibit less airway contractility compared to mice that received the vehicle alone.  
Future Direction 3:  
Establish the ability of miR-708 to inhibit cellular recruitment by HASM cells: 
Since miR-708 and miR-140-3p inhibit release of CCL11 and CXCL12 by HASM 
cells, respectively, migration assays will be performed with culture supernatants 
of HASM cells transfected with mimic of miR-708, mimic of miR140-3p or 
scrambled sequence mimic and activated with TNF-α to examine recruitment of 
human eosinophils and Jurkat cells (a human T cell line), respectively, in 
Transwell chamber plates. We anticipate that there will be less cellular migration 
with culture supernatants from cells transfected with mimic of miR-708 or 
miR140-3p relative to culture supernatants from cells transfected with scrambled 
sequence mimic. 
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Perspectives of the current study 
• Previous studies from our laboratory showed that airways of allergen 
challenged CD38 -/- mice were hyporesponsive   to contractile agonist 
methacholine compared to that of wild type mice.  Airway smooth 
muscle (ASM) cells derived from CD38 -/- mice also showed reduced 
calcium responses to contractile agonists compared to that of wild type 
mice.  These studies revealed the significant role of CD38 in calcium 
signaling and airway hyperresponsiveness (AHR). Further, it has been 
found that signaling pathways MAPK and PI3K regulate TNF-α 
induced- CD38 expression and ASM cells of asthmatic patients have 
increased expression of CD38 when compared to ASM cells from 
healthy subjects.  In the current studies, microRNAs miR-708 and miR-
140-3p are shown to control the expression of CD38 directly by binding 
to the 3’UTR and indirectly through MAPK and PI3K signaling 
pathways. Collectively, these data suggest that the microRNAs miR-
708 and miR-140-3p may have a potential role in attenuating AHR by 
controlling the expression of CD38. 
• The signaling pathways MAPK and PI3K also regulate the expression 
and release of many proinflammatory cytokines and chemokines. In 
asthma, proinflammatory mediators trigger these signaling pathways to 
produce tremendous amounts of chemokines and cytokines in the 
airways that augment and sustain the inflammation. Administration of 
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pharmacological inhibitors of MAP kinases or PI3kinases in allergen 
induced mouse asthma models reduces the airway inflammation. In 
the current study I found that microRNA miR-708 controls the signaling 
pathways MAPK and PI3K by inactivating JNK MAPK and AKT and 
increases the expression of their phosphatases MKP-1 and PTEN 
respectively. Thus introduction of mimics of miR-708 in the airways to 
target ASM cells would cause a high impact in controlling airway 
inflammation. Validation of the reduced mRNA expression of many 
chemokines and the reduced release of CCL11 following miR-708 
transfection in human ASM cells compared to control, further support 
this hypothesis. Likewise, microRNA miR-140-3p inactivates p38 
MAPK and transcription factor NF-κB, and inhibits the mRNA 
expression of many chemokines and the release of CXCL12. Thus 
miR-140-3p may also have a therapeutic potential in controlling airway 
inflammation. Further it has been shown by other laboratories that 
CD38 is essential for dendritic cell trafficking from peripheral tissues to 
regional lymph nodes, T-cell antigen priming and chemotactic 
migration of neutrophils. Thus regulating the expression of CD38 in 
these cells by microRNAs miR-708 and miR-140-3p, we might be able 
to control the airway inflammation. 
• Another aspect of CD38 in contributing to the pathogenesis of airway 
inflammation would be through production of a purine nucleoside, 
adenosine. It is known to be produced from ATP and hypothesize to be 
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produced through the enzymatic activity of CD38 from the substrate 
NAD, which also acts as a source for the production cADPR, a potent 
Ca++ releaser from intracellular Ca++storages.  Adenosine is highly 
expressed in the airways of asthmatic patients and has been shown to 
elevate the expression of IL6 through STA3 activation. IL6 is involved 
in the proliferation of fibroblasts and ASM. Further adenosine binds to 
its receptor A1R on the membrane of ASM cells and induce the 
production of IP3 (inositol triphosphate) another secondary messenger 
for Ca++release from intracellular Ca++storages. Therefore, by 
regulating the expression of CD38 by microRNAs miR-708 and miR-
140-3p, we may potentially control the airway hyperresponsiveness by 
blocking adenosine-IP3 pathway, airway inflammation by blocking 
adenosine production itself and airway remodeling by hindering the 
adenosine - IL6 pathway.  
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